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Abstract
Osteoarthritis (OA) is the most common type of arthritis or degenerative disease and leads to
chronic and functional disability affecting a patient’s quality of life. The etiology of OA is a
heterogeneous multifactorial disease, with inflammatory, metabolic, and mechanical causes.
Therefore, OA commonly affects a heterogeneous population, ranging widely from the middleaged and elderly populations, although younger people may be affected as a result of injury or
overuse. Moreover, OA is characterized by loss of articular cartilage, changes in subchondral bone,
synovium and supporting structures that ultimately affect all the tissues necessary for joint
function. Despite an increasing awareness of OA as a medical problem, there is a surprising
absence of effective medical treatments beyond pain control and surgery. The progressive
understanding of the pathophysiology of OA leads to the perception that the disease is not purely
mechanical or aging, and clarification of the signalling pathways and molecular mechanisms is
necessary to the clinical application.
Our lab has demonstrated the importance of Epidermal Growth Factor Receptor/Mitogen Inducible
Gene 6 (EGFR/Mig-6) for joint development. I hypothesized that Mig-6 regulates cartilage
homeostasis. We first started investigating the role of Mig-6 in cartilage using cartilage-specific
(Col2) overexpression of Mig-6 in a mouse model. Using histopathological assessment,
histological and imaging techniques, we concluded that these animals showed significantly greater
cartilage breakdown with aging, while younger Mig-6over/over mice resulted in healthy articular
cartilage. Moreover, μCT analysis showed small but significant reductions in the size of long bones
of Mig-6over/over mice compared to control group (wild type).
To further analyze the in vivo animal model, we subsequently assessed Mig-6 in cartilage using
skeleton (Prx1)-specific overexpression. I again evaluated the morphology of articular cartilage
using histological techniques and long bones of these mice and concluded similar results from the
previous study, I found that mice overexpressing Mig-6 displayed significantly cartilage damage.
Subsequently, we compared the disease progression between mice with cartilage-specific (Col2)
overexpression of Mig-6 and controls after destabilization of medial meniscus surgery (DMM) to
induce post-traumatic osteoarthritis (PTOA). Mig-6over/over mice exhibited behavioural changes

(vertical activity count) and appeared to show accelerated cartilage breakdown in surgically
induced OA. Collectively, these data demonstrate that Mig-6 plays an important mediating role in
articular cartilage homeostasis and development of osteoarthritis. Overexpression of this protein
compromises the joint’s homeostatic mechanisms, predisposing them to accelerated degeneration.

Keywords
Mitogen inducible gene-6, Epidermal growth factor receptor, Osteoarthritis, Sox9, MMP13,
Lubricin (PRG4), Articular Cartilage, Joint Homeostasis, Transgenic Mice
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Summary for Lay Audience

Osteoarthritis (OA) is a slowly progressive degenerative joint disease characterized by loss of
articular cartilage. Our current understanding of the pathophysiology of OA suggests that the
disease is not purely caused by mechanical factors or aging, and clarification of the biochemical
and inflammatory pathways involved is necessary to develop new therapies. The economic and
social impact of OA due to direct medical costs, loss of work time and quality of life are
considerable.
Currently, there are no treatment options available to slow, stop or reverse the course of OA, and
the etiology of the disease is poorly understood. Thus, additional work to reveal the underlying
pathobiology is required if treatment options are to be developed. Therefore, our laboratory has
focused on elucidating the molecular mechanism relevant to OA using animal models, cell and
organ culture, and biochemical techniques.
We have identified that the epidermal growth factor receptor (EGFR) signaling pathway is
involved in regulating the health of cartilage and other joint structures. In particular, we are
interested in a gene called mitogen-inducible gene 6 (Mig-6) that regulates EGFR signaling, and
loss of this protein has been shown to lead to severe joint dysfunction in mice. Using genetically
modified mice lacking Mig-6 in critical joint tissues our laboratory showed that deletion of Mig-6
resulted in thicker articular cartilage with extra, abnormal cartilage surrounding the knee. My
project focuses on whether overexpression of Mig-6 is enough to cause OA.
Indeed, my work shows that higher levels of Mig-6 in cartilage and other joint tissues leads to
faster and more severe OA both during aging and after injury. Altogether, these studies may
indicate Mig-6 and EGFR as potential therapeutic targets in the treatment of osteoarthritis and
similar diseases.
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Epigraph

“Gratitude makes sense of our past, brings peace for today, and creates a vision
for tomorrow.”

― Melody Beattie
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Chapter 1
Literature Review
1.1

The Development of the Skeleton

The skeletal system consists of approximately 206 bones in the adult human, including long bones
(ex. femur), short bones (ex. carpal bone of the wrist), flat bones (ex. skull) and irregular bones
(ex. vertebrae) (1). Bones are responsible for different functions such as: providing support for
muscle, ligament and tendons, permitting them to attach and allowing for free movement;
protection of soft tissues such as brain, spinal cord, heart and lungs from insult and absorbing
shock related to locomotion; and harboring of hematopoietic red bone marrow within the skeleton
(2). Moreover, as an endocrine organ, bone plays a role in energy metabolism and mineral ion
homeostasis due its function as reservoir for calcium and phosphate storage. Importantly, bones
contain two types of skeletal tissue: cortical and trabecular bone. Roughly 80% of the bone is
composed of the cortical compartment which can be found on the outermost surface at the
diaphysis and metaphysis of long bones, as well as the outer surface of the irregular, short and flat
bones. Cortical bone presents hard and dense tissue and is responsible for the strength of the
skeleton. Trabecular bone comprises 20% of the bone mass, exhibits a spongy appearance and is
situated at the end of long bones and in the inner vertebral space (3). Different cell lineages
contribute to the skeleton during development (4). The onset of skeletogenesis begins with
condensation of mesenchymal cells that either differentiate into osteoblasts to generate bone or
differentiate into chondrocytes to form cartilage templates (anlagen) of future bones (5). Mature
bone is highly mineralized, with a composition of 70% calcium phosphate crystals (mostly
hydroxyapatite [Ca10(PO4)6(OH)2]), 25% of collagenous proteins, cells and other macromolecules,
and 5% of water (6). During embryogenesis, bone tissue is formed via intramembranous bone
formation or endochondral ossification. Intramembranous ossification occurs directly from
precursor cells, when these cells differentiate into osteoblasts that synthesize bone without the
cartilage phase. This process forms parts of the craniofacial skeleton and clavicle (7). In
endochondral ossification, precursor cells differentiate into chondrocytes and produce cartilage
matrix, before replacement of cartilage by bone tissue. This process guides the formation of the
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appendicular and axial skeleton (8,9). Recent studies have shown that proper skeletal development
relies on a variety of cells types and multiple signalling pathways influence bone homeostasis (10–
12). Bone is a highly organized and dynamic connective tissue which is constantly remodelled
throughout life by two processes: bone formation and bone resorption (13). Some bones such as
the flat bones of the skull, shoulder, scapula, pelvis and sesamoid bones are formed by
intramembranous ossification (IO). Mesenchymal cells differentiate into osteoblasts in a process
involving transcription factors such as runt-related transcription factor 2 (RUNX2), Osterix (Osx)
and ATF4 that are essential for osteoblast differentiation and maturation (10). The osteoblasts
produce and secrete collagen type I and proteoglycans to synthesize an osteoid matrix, which is
then calcified to form bone. Ultimately, the osteoblasts differentiate into osteocytes and become
embedded within the formed bone matrix (14). Many different growth factors play a role in
intramembranous ossifications, most notably members of the bone morphogenetic protein family
(such as BMP2, BMP4, and BMP7).

1.1.1

Endochondral Ossification

The majority of our mammalian skeleton consists of bones originating from a cartilage template
intermediate that is then replaced by bone (7,15). Endochondral ossification is initiated during
embryogenesis, and continues until the end of puberty. During this process, condensation of
embryonic mesenchymal stem cells forms the primary template of bone. After condensation,
progenitor cells differentiate to immature chondrocytes that express the transcription factor SRY
(sex determining region Y)-box 9 (SOX9), which is essential for chondrogenesis (16,17). Sox9
has been extensively studied and works with two other members of the Sox family, Sox5 and Sox6,
to constitute the “Sox Trio”(16,18). The Sox Trio activates the expression of aggrecan (Agc1) and
collagen II (Col2a1) genes and thereby controls the synthesis of cartilage extracellular matrix
(ECM) rich in aggrecan and collagen II (19,20). Following mesenchymal condensation and
chondrocyte differentiation, the cells located at the periphery of the cartilage anlagen starts to
flatten and elongate to form the perichondrium (21,22). Ultimately, the chondrocytes in the center
region of the cartilage exit the cell cycle and terminally differentiate into hypertrophic
chondrocytes (23,24). This event occurs around embryonic day 14.5 in mice (e.g., in the tibia).
These hypertrophic cells increase their volume and express type X collagen and the transcription
factor Runx2. Terminal hypertrophic chondrocytes also express molecular markers such as
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metalloproteinase 13 (MMP13), vascular endothelial growth factor (VEGF) and secreted
phosphoprotein 1 (osteopoitin) (25–27). Some of the cells in the perichondrium start to express
osteoblastic genes such as type I collagen (Col1), alkaline phosphatase (Alp), Runx2, among
others, and ECM secreted by these preosteoblast cells initiates ossification adjacent to the
hypertrophic chondrocytes to form a collar of compact bone around the diaphysis of the cartilage
(28,29). In addition, MMP9 is produced by osteoclasts which are activated by RANKL (receptor
activator of NF-kB ligand) produced by hypertrophic chondrocytes (30,31).
During the transition from hypertrophic cartilage to bone, a sequence of events occurs including
mineralization

of

the

cartilage

matrix,

hypertrophic

chondrocyte

apoptosis

and/or

transdifferentiation to osteoblasts, and the invasion of blood vessels that bring osteoblast,
hematopoietic cells and osteoclasts. Collectively, these processes remove the mineralized cartilage
matrix and replace it with bone tissue (32). This results in the formation of primary ossification
center (POC) of endochondral bone. Eventually, the production and maturation of chondrocytes is
restricted to the end of the cartilage (epiphyses) at the growth plate, which is responsible for
longitudinal bone growth in the body (33). At approximately postnatal day 5-7, the secondary
ossification centers appear within the epiphysis in mice, separating the growth plate from the distal
ends of the long bones (34).

1.1.2

Epiphyseal growth plate development

The growth plate forms during fetal developmental and the closure of the epiphyseal growth plate
occurs in late puberty in humans, under the influence of of estrogen in both sexes (35–37). The
elongation of the long bone is the main function of the growth plate (38). The growth plate is a
thin layer composed of highly organized chondrocytes and can be divided into four distinct zones:
proliferative, resting (reserve), hypertrophic and prehypertrophic chondrocytes is also shown in
figure 1.1.
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Figure 1.1 Schematic representation of the growth plate. The endochondral growth plate is
composed of distinct cell zones of resting, proliferative, pre-hypertrophic and hypertrophic cells.
A series of cellular differentiation stages occurs from resting cells to hypertrophy, resulting in
longitudinal bone growth, largely because of the proliferation and enlargement of chondrocytes.

5

Figure 1.1 The Growth Plate
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The resting or reserve zone contains small and round cells, with high volume of extracellular
matrix but low metabolic activity (39,40). Moreover, a recent study has shown that the resting
zone includes stem-like cells that will generate proliferative chondrocytes; deletion of resting
chondrocytes leads to growth plate senescence (41,42). The proliferative zone is composed of
columnar chondrocytes which undergo rapid cellular division in direction towards the diaphysis
which leads to longitudinal bone growth. These cells express Col2a1 and Aggrecan genes to
synthesize the cartilage-specific matrix (43). When chondrocytes exit from the cell cycle, they start
to increase their cell volume and enter first the prehypertrophic zone, and then the hypertrophic
zone. Hypertrophic chondrocytes express collagen, type X (Col10a1) (44). Late hypertrophic
chondrocytes initiate expression of MMP13, VEGF, and alkaline phosphatase (45). Growth plate
chondrocyte proliferation and maturation is regulated by systemic and local factors that include
different hormones, growth factors, and multiple signaling pathways. For example, growth
hormone (GH) induces the production of insulin-like growth factor I (IGF-1) which promotes
chondrocyte proliferation and initiates chondrocyte hypertrophy (46). IGF-1 signaling also
interacts with the Indian hedgehog (Ihh), parathyroid hormone related peptide (PTHrP), and Wnt/β
-catenin pathways that are crucial during skeletal development (47–49). In addition, some studies
have shown that thyroid hormone is essential for skeletal growth and that hypothyroidism leads to
bone growth retardation, delayed bone age, and short stature (50,51). Taken together, a number of
transcription factors and signaling pathways mediate the epiphyseal growth plate through the
fascinating interaction between cell types which can help to elucidated human skeletal dysplasia’s
involvement in this process.

1.1.3

Secondary Ossification Center

During early postnatal development the secondary ossification center (SOC) is formed and
separates the growth plate from the articular cartilage (52,53). Differently from the POC, SOC
formation is not preceded by the formation of hypertrophy and mineralization of cartilage or of a
bony collar (54,55). The first event in secondary ossification is the vascular invasion of uncalcified
hyaline cartilage of the epiphysis (perichondrium), enabling the infiltration of osteoclast and
osteoblast cells (56,57). Studies have identified high expression levels of MMPs around forming
blood vessels and at the borders of the marrow cavity, allowing for remodeling of the extracellular
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matrix, which is necessary for ossification of the epiphysis (58). Accordingly, it has been also
reported that VEGF is required for neovascularization of hypertrophic cartilage to enhance the
vascular ingrowth of growth plate in this region (55). Interestingly, the last phase of the
endochondral ossification is the mineralization process. Following the calcification of the
extracellular matrix by hypertrophic chondrocytes and vascular invasion, osteoclasts break down
cartilage (28). At the same time, osteoprogenitor cells are recruited and differentiate into
osteoblasts that secrete osteoid, which forms the bone trabecula within the growth plate resulting
in mature secondary ossification centers (59,60). Many signaling pathways interact with each other
to regulate this process, such as WNT/ β-catenin signaling (61,62) and epidermal growth factor
(EGFR) to fine tune bone development (63).

1.1.4

Synovial Joint Development

Joints are structures where adjacent bones are held together by connective tissue. Synarthroses
(syn= together + arthrosis = articulation) can be divided into: 1) fibrous joints, in which skull
bones from children and young adults are connected by layers of connective tissue; for example,
sutures; 2) cartilaginous joints are found between bones that articulate against each other with a
pad of fibrocartilage; for example, the intervertebral discs of the spinal column; 3) synovial joints,
where the adjacent bones are in contact with each other within a sealed joint cavity that contains
synovial fluid; for example, joints of knees, elbows or ankles (64,65). Synovial joints from mice
are formed through a series of steps between E12.5 and E13.5 days. Growth/Differentiation factor
5 (GDF5) is important in defining the interzone between adjacent cartilages (66,67). The interzone
zone originates from condensed mesenchymal cells that express the “Sox trio”, Col2a1, and Agc1
but also Wnt9a, Wnt4 and Noggin which are important anti-chondrogenic factors (19,68–73). The
exact balance of these pro- and anti-chondrogenic factors is crucial for the formation of articular
cartilage and non-cartilaginous joint structures (such as ligaments, synovial lining) (73). Cell
apoptosis also contributes to formation of the joint area. The joints from mice are completely
formed by E16.5 days. Interestingly, mechanical stimuli through the movement of muscle
contraction is an important factor for joint progenitor cells (74). Previous studies have shown that
mechanical forces can contribute to the development of joint formation as well as endochondral
ossification (75).
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Anatomically, the synovial joint is comprised of different tissues including articular cartilage,
synovial membrane, subchondral bone, ligaments, tendons and meniscus (Fig. 1.2). Altogether
theses tissues play a role in maintaining the homeostasis of the joint (76,77). The main function
of articular cartilage is to minimize friction upon joint movement and to distribute loads (78). The
collagen network of the hyaline articular cartilage enables even distribution of the forces generated
by mechanical compression (79). The joint cavity is enclosed by a specialized fibrous connective
tissue including the synovial membrane that extends folds and villi into the joint cavity and secretes
the lubricating synovial fluid (80). Synovial fluid is derived from blood plasm, but with a high
concentration of hyaluronan (HA) produced by cells of the synovial membrane. Cells of the
synovial membrane include macrophage-like synovial cells (type A cells) and fibroblastic synovial
cells (type B cells) (81–83). Subchondral bone is the zone of epiphyseal bone underneath the
articular cartilage and its main role is to form the “osteochondral junction”, which is related to
biomechanical and biochemical cross-talk between articular cartilage and underlying bone
(84,85). Another supporting structure in the knee joint is the meniscus, which is a C-shaped
fibrocartilaginous tissue between the tibia and femur. Knee meniscus is important to allow smooth
load transfer from femur to tibia and for joint stability (86,87).
Subchondral bone consists of two distinct structure: subchondral bone plate (SBP) and
subchondral trabecular bone (STB), which form a unit that separates the articular cartilage from
the bone marrow (88). The main functions of the subchondral bone are to dissipate forces and
provide elasticity for shock absorption caused by repetitive loading such as locomotion.
Furthermore, subchondral bone has an extensive local response to repetitive loading though the
bone remodeling process (89). It has since been shown the subchondral bone is a highly
vascularized, innervated and dynamic tissue which provides a connection between the uncalcified
cartilage and the bone marrow space (90). In fact, many signaling mechanisms facilitate the
communication between articular chondrocytes and subchondral bone cells (osteoblast, osteoclasts
and osteocytes) (91). Another important function of subchondral bone is to deliver nutrition and
oxygen supply to cartilage through the medullary cavity via channels that connect subchondral
bone and cartilage (92).
Moreover, synovial joints are reinforced by a number of extracapsular ligaments that are made
from bands of dense regular connective tissue that connect bones to other bones (93). Skeletal
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muscle mediates movement/locomotion and also helps to stabilize the joint. Every joint has
nervous innervations related to nociception and neurogenic inflammation; sympathetic and
sensory nerve fibers are present in synovium, subchondral bone, and periosteum (94,95).

1.2
1.2.1

Cartilage
Composition of Cartilage

Cartilage is an avascular, aneural and alymphatic tissue that mainly consists of ECM and water,
comprising more than 95% of tissue volume (96,97). There are three major types of cartilage:
elastic cartilage, fibrocartilage and hyaline cartilage. Elastic cartilage is found in the epiglottis (part
of the larynx) and the pinnae (external part of ear flaps) and is composed of collagen fibers and
elastin protein (98,99). Fibrocartilage is found in the pubic symphysis, the annulus fibrosus of
intervertebral discs, menisci and the temporal mandibular joint. Fibrocartilage is also largely
composed by type I collagen (100,101). Hyaline cartilage can be found on many joints surfaces
(ex. articular surfaces of long bones) as well as at the epiphyseal plate (growth plate) (102), as
previously discussed. Histologically distinguishable from the other types of cartilage, the ECM of
hyaline cartilage is mainly composed of collagen type II, proteoglycan, water and lesser amounts
of other non-collagenous proteins and glycoproteins (103). More specifically, these proteoglycans
consist of core protein (210-250 kDa), mostly aggrecan, that is the most abundant by weight and
largest in size in the ECM of cartilage. Aggrecan has many glycosaminoglycan (GAG) side-chains
and binds to hyaluronic acid (HA) polymers to form a large complex with negative charges, which
contributes to its function (104). The GAG chains are composed of chondroitin-sulfate and keratan
sulphate with a high water-binding capacity and provide osmotic properties to cartilage, which
will ultimately contribute to retain water within the ECM (105,106). Moreover, the principal
collagen in the ECM of articular cartilage is the type II collagen. Articular cartilage, collagen type
II, provide tensile strength and physical properties of the mature matrix. Also, collagens IX and
XI are responsible to stabilize and help in the organization of the collagen network.
Together, these components and structures provide the cartilage function as a very resilient and
highly specialized tissue that forms the smooth gliding surface of synovial joints, as well as, shear
strength and self-lubrication (107). Articular cartilage has limited self-repairing capacity; the
amount of cartilage ECM decreases with age and this has been attributed mainly to diminished
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anabolic activity of cartilage cells (108). The cellular component of cartilage is made up by only
one cell type, the chondrocytes which occupy about 2% of the volume of human cartilage (109).
In healthy cartilage, chondrocytes produce proteolytic enzymes that act on collagen and
proteoglycans, promoting localized and controlled tissue turnover and repair. The half-life of
collagen is from several decades to up to 400 years for human femoral head cartilage, however,
the average half-life of aggrecan is 25 years (110). The homeostasis of matrix turnover in articular
cartilage will be explained later in this chapter but involves a dynamic equilibrium involving
biochemical mediators including hormones, growth factors and cytokines as well as mechanical
forces (111).

1.2.2

Zones of Articular Cartilage

Articular cartilage is composed of four different zones: superficial zone, middle zone, deep zone,
and calcified zone. Within each zone, 3 different regions can be identified: the pericellular region,
the territorial region, and the interterritorial region. The superficial zone (SZP) is the outermost
layer of articular cartilage, protects deeper layers from shear stress, and makes up roughly 10% to
20% of articular cartilage thickness (112). Collagen type II is aligned parallel to the articular
surface, but there is less aggrecan in the SZP (113). This zone is in contact with synovial fluid and
is responsible for most of the tensile and compressive stiffness of cartilage to resist shear forces
during joint movement (114).
In the superficial zone, the chondrocytes are smaller and flattened in morphology and have a
greater density (115). Interestingly, mesenchymal stem cell markers have also been detected in the
superficial zone of adult articular cartilage, suggesting a potential role in endogenous repair or
cell-based therapy for treating some diseases such as osteoarthritis (OA) (116). However, more
research is needed to elucidate the activity of these progenitor cells and the involvement of
signalling pathways that regulate their functions. Importantly, the chondrocytes in this zone
express several molecules such as superficial zone protein (SZP), also known as lubricin (PGR4)
(117). Likewise, hyaluronan and surface-active phospholipids (SAPL) are involved as key
boundary lubricants in cartilage (118). The middle (transitional) zone (MZ) is the largest zone that
represents 40% to 60% of the total cartilage volume and acts as a first barrier in resisting the
compressive loads between the superficial and deep zone, due to collagen fibrils organized
obliquely from articular surface to subchondral bone (112,119). Recent studies have shown the
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importance of the middle zone for the biomechanical resilience. MZ chondrocytes are spherical
and large cells, with a column-like stacked arrangement (119). Below the MZ is the deep zone
(DZ) that comprises 30% of cartilage volume and also contributes to its compressive strength. The
DZ is characterized by vertical and columnar type II collagen fibers and proteoglycan organized
perpendicular to the articular surface (120). In this layer, the chondrocytes are rounded and
arranged as vertical columns of cells (121,122). The final layer is the calcified zone of cartilage
(CZC), the deepest zone characterized by a calcified cartilage matrix which ultimately contributes
to dissipating shock absorbance and confers structural integrity between the tissues of cartilage
and bone during loading. Moreover, the calcified zone contacts the underlying subchondral cortical
bone, known as the articular cartilage end plate (123). The cells in this layer are hypertrophic
chondrocytes producing type X collagen, and the cell density is relatively low compared to the
other zones (124). The deep zone is separated from the other zones by an irregular thin cement line
known as tidemark (125).

1.2.3

Extracellular matrix and chondrocyte interaction

The cartilage ECM contains proteoglycans, collagens, cell binding glycoproteins, non-collagen
ECM proteins, and lipids (126,127). The ECM can be divided into different regions such as:
pericellular, territorial and interterritorial. The chondrocyte and its PCM environment is termed as
chondron, which is surrounded by the territorial matrix including type XVI collagen (127). Type
XVI collagen organize the ECM by anchoring and stabilizing collagen fibrils and sustaining
microfibrils, intercepting intracellular signalling involved in proliferation and cell adhesion. The
territorial matrix is made up of fine collagen fibrils containing types II and XI collagen is involved
in the protection of chondrocytes from mechanical load and may facilitate the resiliency of articular
cartilage to load bearing (126,128). The largest region is the interterritorial region that is composed
mostly of proteoglycans and randomly oriented collagen fibrils which contribute to the
biomechanical properties of articular cartilage (129).
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1.2.4

Cartilage Molecular Mechanism of Cartilage Homeostasis: Catabolic and
Anabolic Factors

Joint movement and dynamic loading of articular cartilage play crucial roles in the joint
homeostasis and the pathogenesis of OA. The process by which chondrocytes convert mechanical
signals into biochemical responses is called chondrocyte mechanotransduction (130). During joint
loading, the compression of cartilage results in altered matrix water content and osmotic pressure,
complex changes in calcium concentration, and fluid shear stress (131). Moreover, excessive
mechanical loading can also influence the physiological balance between catabolism and
anabolism factors, resulting in the development of diseases such as OA (132). Many candidate
mechanoreceptors have been identified in chondrocytes including integrins, stretch-activated or
stretch-sensitive ion channel (SACs), connexins, and primary cilia (133). These mechanoreceptors
initiate intracellular signaling cascades leading to articular cartilage remodeling (134). Under
physiological loading, chondrocytes maintain homeostasis. Unphysiological stimulation, however,
can lead to changes in the chondrocyte phenotype, such as de- differentiation to a fibroblast-like
cell and decrease of production of cartilage specific makers including type II collagen and
aggrecan, or the induction of chondrocyte hypertrophy and apoptosis (135).
Healthy joint tissue under mechanical loading conditions has appropriate anabolic responses to
antagonize the process of catabolic cytokines. One of the most important anabolic factors for
articular cartilage, insulin-like growth factor-I (IGF-I), has been implicated in proteoglycan
production. Many studies have demonstrated that IGF-I plays a role in chondrogenesis by
enhancing proliferation and stimulating expression of collagen II and Sox9 (136). Furthermore,
the TGF-β family members such as: bone morphogenetic proteins (BMPs), GDF5 and TGFβ itself
(137). Members of the FGF family including FGF-10 and FGF-18 have anabolic effects on
cartilage tissue at early stages of development (138). Interestingly, FGF-18 induces cartilage
matrix production by activating the FGF receptor 3 (FGFR3) (139). As stated above, during life
time, chondrocytes are responsible for the maintenance of the articular cartilage by regulating
matrix

metalloproteinases

(MMPs)

and

A

Disintegrin

and

Metalloproteinase

with

Thrombospondin Motif (ADAMTSs), collagen II and aggrecan networks surrounding them (140).
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In summary, a variety of stimuli (chemical, inflammatory, growth factors and other signalling
factors) can contribute to the anabolic and catabolic balance on cartilage and OA pathogenesis.
Catabolic event is marked by cartilage matrix degradation markers, such as proinflammatory
cytokines including interleukin-1-beta (IL-1β) and tumor necrosis factor-alpha (TNFα) (141).
Evidence from in vitro and in vivo studies have demonstrated that TNFα and IL-1β contribute to
ECM destruction and induce chondrocyte apoptosis (142). In addition, IL-1β can enhance
expression of MMP-1, MMP-3 and MMP-13(143). Other inflammatory cytokines such as IL-4
have been reported as well in human articular cartilage, and IL-1, -6, -8 are increased in the
osteoarthritic synovial lining (144). ADAMTS proteins are proteases that target aggrecan. IL-1β
and TNF-α stimulate the production of ADAMTS-4 (145) through activation of the transcription
factor NF-κB, as well as p38 and c-Jun N-terminal kinase (JNK) MAP kinases (146).

1.3

Osteoarthritis

Currently, there are more than 100 different forms of arthritis, and the most common form is
osteoarthritis (OA). It has been estimated that currently 250 million people are affected by OA
worldwide (147). The burden of OA is increasing substantially in Canada and the United States,
including direct and indirect economic costs. More research is needed to enable a better
understanding of the pathophysiology of OA, and clarification of the underlying signalling
pathways and molecular mechanisms is necessary to direct the clinical approaches to disease
management.

1.3.1

Etiology of Osteoarthritis

OA is a heterogeneous pathology characterized by many different factors involving metabolic,
inflammatory, and mechanical causes. The classification of OA has traditionally been
subcategorized into idiopathic (ie, primary) in nature, with no known specific cause, and secondary
OA (148). Both primary and secondary OA involve the deterioration of cartilage in joints, and
bones begin to rub against one another. However, primary and secondary OA have different
triggers. For example, primary OA is affected by several factors including obesity, gender, age,
and genetic factors that can lead to the development of OA (149). Contrarily, secondary OA or
posttraumatic OA, is caused by trauma that directly damages joint tissues and destabilizes the joint
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(i.e. meniscectomy or anterior cruciate ligament (ACL) tears). Abnormal anatomical stress such
as femoroacetabular impingement (FAI), or malalignment of the tibia and femur of the knee
resulting in ‘knock-kneed’ or ‘bow-legged’ (valgus and varus, respectively) can contribute to OA
susceptibility (150,151).

1.3.2

Non-Modifiable Risk Factors For OA

Although the cause of OA is still unclear, there are non-modifiable and modifiable risk factors for
OA. Age is one of the greatest non-modifiable risk factors for the development of OA as a result
of many biological age-related changes in the joint structures. In fact, 70% of women and 60% of
men over the age of 65 years were diagnosed with radiographic signs of OA in one or more joints
(108,152). Moreover, several studies have demonstrated that senescent chondrocytes are found in
degenerated cartilage tissue and cartilage tissue from OA patients undergoing joint replacement
surgery (153). Senescence of chondrocytes is associated with development or progression of OA,
since the senescent cells show increased production of MMPs and catabolic degradation of type II
collagen (154).

Several pathways such as p38 MAPK and PI3K/Akt are involved in the

senescence-associated secretory phenotype (SASP) (155). Furthermore, OA chondrocytes display
more production of reactive oxygen species (ROS) due the mitochondrial dysfunction, which may
increase inflammation and catabolic responses mediated by NF-kB pathways (156). In vivo studies
have also demonstrated that mechanical injury to cartilage can lead to senescence in the superficial
zone in young animals and throughout cartilage in aged animals (157). In addition, with age,
changes in other tissues such as subchondral bone changes, loss of muscle mass (sarcopenia),
synovium and ligament changes, can contribute to the onset of OA development (158–160).
According to World Health Organization (WHO) the prevalence of OA is higher in women (18%)
than in men (9.8%), particularly in those above 60 years of age. Some studies have shown anatomic
differences between women and men, with women showing significantly tibiofemoral cartilage
defects and tibial and patella cartilage loss (161). Moreover, a study comparing the kinematic
differences between male and female athletes demonstrated that women exhibited greater anterior
and posterior shear forces, knee extension and valgus moments, which may also play a role in the
development of knee OA in women (162,163). In vivo studies have suggested that sex hormone
deficiency influence joint structure as shown in orchiectomized (ORX) male and ovariectomized
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(OVX) female mice (164). As a result, intact male mice had more accelerated OA development
than ORX male, however, OVX female mice had more severe OA than intact female. But the
direct actions of estrogen or testosterone on cartilage are still unclear (165). A large number of
studies have shown the contribution of genetics and epigenetics in OA, which is estimated to be
between 40% and 80%, and higher in hand and hips than for knee OA (166). An inherited
predisposition to OA has been evidenced for many years from twin and sibling studies (167). The
past decade has identified a great number of candidate genes that confer susceptibility for OA
disease. Previous findings using genome-wide associated studies (GWAS) have identified GDF5,
COL2A1, TGFB1, Matrilin 3 (MATN3), IL1, and IL4R as contributors to OA risk in different
joints (168–170).

1.3.3

Modifiable Risk Factors For OA

The most significant modifiable risk factor in OA is obesity, since weight loss in OA can benefit
patient pain significantly and slow down progression of joint structural damage. Obesity affects
the weight-bearing joint by altering joint kinematics and increasing ambulatory load (173).
Interesting, there also is evidence that obese people are at increased risk for developing hand OA
due the metabolic association between adipose tissue and OA (174). Adipokines such as leptin
have been identified in articular cartilage and synovial fluid from knee or hip OA patients (175).
Moreover, the systemic inflammatory effect of increased adipose tissue leads to
“metainflammation” (inflammatory and metabolically active) involving proinflammatory
cytokines that have a role in joint structural change and in the perception of pain, altogether
contributing to a positive feedback loop of obesity and OA (176).
Different tissue in the joint can be affected due to either a single episode of trauma or repetitive
overuse. Studies have shown structural damage resulting from mechanical forces from highimpact exercise on cartilage tissue, which can lead to the incidence of secondary OA(177).
Meniscal or anterior cruciate ligament (ACL) injury arise frequently from joint trauma (sports
injuries, falls, occupational activity) and present a risk factor for OA (178). Joint trauma induces
to a complex metabolic response that involves cell death, matrix degradation, release of oxidants
and inflammatory cytokines, potentially causing further joint damage (179). A synovial
inflammatory response is a regular consequence following injury. Moreover, mechanical
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instability often results from joint injury (e.g. ACL rupture), leading to an unbalanced load
distribution and cartilage degeneration (180). Thus, direct trauma to joint structures, an
inflammatory response, and mechanical instability all contribute to the risk of post-traumatic OA.

1.3.4

Pathobiology of Osteoarthritis

OA is characterized by failure of the synovial joint organ as a result of dysfunction of one or more
joint structure (as shown in Figure 1.2), resulting in joint pain and increasing disability. Indeed,
subchondral bone, synovium, supportive ligaments and articular cartilage all play a role in
progression of OA pathology.
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Figure 1.2 Synovial joints in health and OA knees. The articular surfaces of bones within
synovial joints are covered with a thin layer of hyaline cartilage that provides a smooth surface
and reduces friction during movement. Moreover, articular cartilage enables the subchondral bone
to absorb and dissipate impact energy during weight bearing. The fluid-filled joint cavity is
enclosed by a fibrous joint capsule. The synovium (synovial membrane) lines the joint cavity and
produces synovial fluid which provides nutrition and lubrication to the cartilage surfaces. In
addition, other structures such as ligaments, tendons and muscle support stability and alignment
of the joint. Menisci are responsible for the distribution of mechanical loading in the femorotibial
joint. Figure courtesy of Ermina Hadzic.
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Figure 1.2 Synovial joints in health and OA knees.

19

1.3.5

Cartilage Breakdown in OA

As mentioned before, OA is not simply a disease of cartilage it is, rather, the irreversible
destruction of cartilage which is attributed to OA. At the early stage of OA, articular cartilage loses
its structure and composition due to decreasing proteoglycan content. Once collagen is degraded,
it appears that a state is reached that cannot be reversed (149). Early degenerative changes happen
in the SZP of articular cartilage after successive loads and contribute to the progressive cartilage
destruction (181). Articular cartilage progressively undergoes fibrillation and erosion towards the
calcified cartilage and extends into the mid and deep zone of cartilage (182). The continued
deterioration of articular cartilage eventually exposes the underlying subchondral bone, resulting
in a decrease in joint motion and increase of pain (183). During OA, changes in chondrocyte
behaviour with disease advancement can be seen. Chondrocyte responses and expression profiles
are altered during OA, for example, increased expression of degenerative enzymes (such as
MMP13 and ADAMTS-5) (184). Overall, the alteration in chondrocyte phenotype leads to an
imbalance in anabolic and catabolic processes in articular cartilage and ultimately in the
progression of the disease.

1.3.6

Subchondral Bone in Osteoarthritis

As the disease progresses, not only articular cartilage is deteriorated, but changes in the underlying
subchondral bone also play an important role in the onset of OA (185). The subchondral bone
tissue is a biphasic material and is designed to support axial loads and respond to stresses placed
across the joint structure. Mechanical properties can be associated with bone thickening, increased
porosity, reduced density/elasticity and reduced capacity for shock absorption (89). Current
evidence suggests that subchondral bone disease is part of OA pathogenesis. For example, patients
with hip OA pathology showed an increased volume of trabecular bone as well as higher bone
mineral density (BMD) (186). Moreover, using magnetic resonance imaging (MRI) bone marrow
lesions (BML) (also called bone marrow edema or bone bruises) have been associated with knee
malalignment and knee pain (187). BMLs are strongly associated with pain and related to the
occurrence of subchondral microfractures (188). In order to compensate the mechanical instability
of the joint, osteophytes are formed at joint margins in a process similar to endochondral
ossification, regulated by the actions of TGFβ and BMP2 (189,190). Subchondral bone sclerosis,
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subchondral bone cysts formation, osteophytes, subluxation, narrowing of the joint space and intraarticular or periarticular calcification are commonly seen radiographically in more chronic cases
of OA (191).

1.3.7

Changes in the Synovium

Mounting evidence suggests that the synovium plays an important role as a driver of the OA
process at early and late stages. Synovitis is a complex process and can be induced by release of
fragments from degraded hyaline cartilage as well bone (detritus) structures into the synovial
cavity, which ultimately initiate synovial inflammation (192). Several studies have shown that
synoviocytes produce pro-inflammatory factors that attract immune cells and inflammatory
mediators such as macrophages and T-cell lymphocytes into the OA synovium (78). Cytokines
and chemokines as well as their downstream signalling pathways have been extensively studied in
the synovium, including TNFα, IL-1β, IL-6, IL-15, IL-17, and IL-18 that are up-regulated in OA
synovial fluid and synovial membrane (SM) (193). Moreover, Toll-like receptors (TLRs) are
expressed by macrophages found in SM in both OA and rheumatoid arthritis (RA) (194). TLRs
activate nuclear-factor κB (NF-κB), resulting in the production of chemokines and cytokines such
as IL-8, CCL5, and IL-6 and stimulation of macrophages, granulocytes, and lymphocytes (195).
Aspects of synovitis in knee OA include thickened synovium, villous hyperplasia, increased
synovial vascularity and vascular flow, infiltration of lymphocytes and macrophages, and fibrosis
(196).

1.3.8

Mechanism of OA Pain

The perception of pain is the predominant and most disabling symptom of OA patients and those
affected by pain usually report pain-related psychological distress, swelling, fatigue and morning
stiffness (197). Peripheral mechanism can increase chronic pain and also contribute to hyperalgesia
(enhanced pain response) or allodynia (pain in response to non-noxious stimuli) (198). Nociceptors
(pain-sensing afferent neurons) and proprioceptors (afferent receptors for motor control) are
present in tissues that are compromised by OA, including the periosteum and subchondral bone,
soft tissues including ligament insertions, menisci, and synovium that ultimately leads to the
feeling of joint pain (199). Therefore, OA pain is a complex process that involves nociceptive input
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from the joint as well as in the peripheral and central nervous system. Under disease conditions,
many inflammatory mediators are released within the joint to elicit pain (200). Synovium in OA
patients has “macroscopic” inflammation that can corroborate to the pain within the joint, since
cartilage debris can be phagocytosed by cells lining the synovium (201). Articular cartilage is
anural and avascular, however, the degeneration in cartilage that leads to subchondral bone plate
exposure is associated with prevalent and incident knee pain in patients with knee OA (202).
Furthermore, there are many signaling pathways contributing to the mechanism underlying OA
pain.

Chemotactic cytokine ligand 2 (CCL2) signalling has been identified as nociceptive

stimulator in the development of pain in mice (203). Clinical and animal studies have targeted
nerve growth factor (NGF) and inhibition of its receptor, tropomyosin receptor kinase A (TrkA),
in OA pain. Interesting results have shown the efficacy of targeting NGF on reducing OA pain, as
seen in patients that had treatment with the anti-NGF antibody tanezumab (204). However, more
clinical and animal studies are required for understanding the role of the NGF/ TrkA pathway in
OA to optimize therapeutic strategies for OA.

1.3.9

Diagnosis and Treatments for OA

OA commonly affects multiple joints such as hands, knee, hips and spine, and plain radiograph (xrays) or advanced imaging techniques including MRI or computed tomography (CT) can be also
used for diagnosis of OA pathology (205). Radiography enables the visualization of marginal
osteophytes, subchondral sclerosis and cysts, cortical alterations and alignment of the joint. Other
joint structures such as articular cartilage, crucial or collateral ligaments, and menisci are more
easily visualized by MRI (206). Furthermore, (CT arthrography (CTA) and MR-arthrography
(MRA) can also identity articular cartilage, synovial inflammation, and osteophytes with high
anatomic resolution (206). Additional guidelines to diagnose OA include: pain is enhanced with
activity of daily living; morning stiffness with duration of less than 30 minutes; range of motion
becomes limited with joint locking or joint instability; and patients older than 45 years (207,208).
The treatment for OA patients is focused on relief of pain, and improvement/maintenance of
quality of life. OA treatment can be divided in three categories: nonpharmacologic, pharmacologic
and surgical management (207). In order to control pain, the use of nonsteroidal anti-inflammatory
drugs (NSAIDs) is recommended, such as acetaminophen or cyclooxygenase-2 (COX-2)
inhibitors (209). Moreover, intra-articular therapies can also be used for acute pain, such as
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hyaluronic acid (HA) or corticosteroid (CSs) injections; however, variable and controversial
results have been reported in clinical trials and meta-analysis (210,211). Non-pharmacological
management includes weight reduction and targeted exercise; for example, low-impact activities
have shown improvements in pain and physical performance for OA patients (212,213). The last
option for OA treatment is total joint replacement; however, it is not a final resolution for OA
disease, since most of the joint prostheses will function well for 15 to 20 years, not a life time
(214). Complications post-surgery are not uncommon (215).
Clearly there is a need for new OA treatments, in particular disease-modifying drugs that can slow
stop, or reverse OA progression. For example, strategies aimed at synovial fluid (targeting
activated macrophages), C reactive protein, cytokines and adipokines/hormones are under research
for OA treatment (320,321). However, a more detailed understanding of the molecular
mechanisms driving OA might identify more drug targets.

1.4
1.4.1

Signaling Pathways in Osteoarthritis
Receptor Tyrosine Kinase Signaling in Osteoarthritis

Many different signal proteins act via receptor tyrosine kinases (RTK), such as epidermal growth
factor (EGF) receptor, insulin receptor, insulin-like growth factor (IGF1) receptor, nerve growth
factor receptor, vascular endothelial growth factor (VEGF) receptors, and others (218). In most
cases, the activation of RTKs occurs through the binding of the signal protein to the ligand-binding
domain on the extracellular side of the receptor. This results in dimerization, bringing the two
cytoplasmic kinase domains together and allowing trans-autophosphorylation and activation.
However, there are some important exceptions, for example EGFR.
EGFR is a type 1 transmembrane glycoprotein that is a member of a family of 4 receptor tyrosine
kinases (EGFR or ErbB1; Her2 or ErbB2; ErbB3; and ErbB4) ref. Several ligands can bind to
EGFR with high affinity: epidermal growth factor (EGF), heparin-binding EGF-like growth factor
(HB-EGF), transforming growth factor α (TGFα), and betacellulin (BTC). EGFR also has 3 low
affinity ligands: epigen (EPGN), epiregulin (EREG), amphiregulin (AREG) (219–221). These
ligands for EGFR are found as type 1 transmembrane pro-forms and are shed from cell surface
(222–224). Together, EGFR can form either homo- or heterodimers with other ERBB receptors,
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especially ERBB2 (225). ErbB2 and ErbB4 are capable of forming heterodimeric pairs with each
other due their catalytic kinase domains. On the other hand, ErbB3 has an inactive kinase domain
that can still pair with and activate the other ERBB receptors. Several studies have demonstrated
that members of the ADAM (a disintegrin and metalloproteinase) family such as ADAM17 or 10
can induce EGFR transactivation through shedding of the ligands from the membrane (226). Under
unstimulated conditions, EGFR is found at the plasma membrane in an auto-inhibited state,
however, ligand binding leads to receptor dimerization and activation of RTK activity. Ligandbinding to the receptor causes a conformational change in its dimerization arm, which forms an
asymmetric dimer. Thereby, this dimer phosphorylates multiple tyrosines in the C-terminal tails
segments of both EGFR receptors (227). This triggers the assembly of an intracellular signaling
complex that can activate many downstream pathways, including MAPK/ERK, PI3K/Akt, SRC,
PLCγ/PKC, and JAK/STAT, as shown in Figure 1.3. The biology of ErbB receptors, including
their structure, signaling, biochemistry, genetics, and their roles in development and disease have
been studied extensively (228,229).
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Figure 1. 3. Activation of Epidermal growth factor receptor and signaling pathways.
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that signals via many
downstream pathways. Activation of EGFR is triggered by several ligands. These ligands for
EGFR family are found as type 1 transmembrane pro-forms and are shed from cell surface by
members of the ADAM family such as ADAM17 or 10. Ligand binding results in either homo- or
heterodimers of EGFR and activation of downstream pathways such as mitogen activated kinase
(MAPK) cascades, JAK/STAT, Rho GTPases and various PKC family proteins,

P13K

(phosphoinositide 3-kinase). EGFR activation of these pathways is cell type specific. Mig-6 is a
transcriptionally feedback inhibitor and has crucial activity in regulating EGFR signaling through
two different mechanisms: inhibiting the catalytic activity of EGFR by docking the kinase domain
and driving EGFR into endocytosis.
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Figure 1.3 Epidermal growth factor receptor activation and signalling pathways
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Deregulation of receptor tyrosine kinase signalling leads to the development of a variety of human
diseases including non-small cell lung cancer (NSCLC), squamous cell carcinoma (SCC), large
cell carcinoma (LCC) and osteosarcomas (230,231). Studies have shown a dual role for EGFR
signaling in OA context related to the development, protection and destruction of articular cartilage
(232–237). Some studies have found that EGFR is an anabolic regulator of bone formation as it
maintains mesenchymal stem cells and osteoprogenitors in bone (238). A previous study has
shown that EGFR can activate the MAPK/ERK pathway to induce osteoprogenitor proliferation
and survival, and therefore can promote bone formation (239). Cartilage-specific Egfr knockout
mice showed elongated growth plate due to down-regulation of MMPs (9, 13 and 14) and RANKL
in the growth plate and subsequent delays in the conversion of cartilage to bone (238). Another
study showed that MMP9 and RANKL are upregulated by EGFR via the canonical Wnt/β‐catenin
pathway (240).
Several studies have implicated EGFR and its ligands in OA. Previous studies have shown that
EGF has been identified in rheumatoid arthritis (RA) and TGFα in the synovial fluid of OA patients
(241,242). Interestingly, in vitro studies using chondrocytes treated with EGF showed chondrocyte
phenotype alteration and up-regulation of inflammatory markers (242,243). In addition, heparinbinding epidermal growth factor-like growth factor (HB-EGF )is highly increased (494%) in joints
of 12 month-old mice that underwent DMM (destabilization of medial meniscus) surgery to induce
post-traumatic OA (244). Our lab has shown that TGFα mRNA and protein expression was
increased in rats that underwent a surgical procedure to induce OA (transection of the anterior
cruciate ligament with partial medial meniscectomy) (232). Moreover, TGFα supresses expression
of anabolic genes such as Sox9, type II collagen and aggrecan, but induces MMP13 as well as
TNFα in chondrocytes (233). Additional in vitro and ex vivo experiments using chondrocyte
culture and osteochondral explants have demonstrated that activation of EGFR signalling in
articular cartilage promotes cartilage degeneration and chondrocyte proliferation (245), and
inhibits chondrogenesis (246). Evidence of the importance of TGFα/EGFR in OA stems from
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analyses of young Tgfa KO mice that are protected from developing OA after DMM surgery, but
there was no protection when surgery was performed in older mice or during normal aging (247).
Furthermore, pharmacologic inhibition of EGFR by AG1478 led to decreased progression of
cartilage damage in a rat model of posttraumatic OA (248). Furthermore, the human TGFA gene
is also reported amongst the genetic loci most strongly linked with OA and cartilage thickness in
two genome-wide association studies (GWAS) (171,249). On the other hand, EGFR signaling
plays a crucial role in articular cartilage development and for maintaining proliferation and
survival of superficial chondrocytes as well as mechanical strength of cartilage (237,250). Mice
heterozygote for a dominant negative EGFR (EgfrWa5/+) showed accelerated OA at 12 weeks after
DMM surgery with accelerated loss of cartilage and subchondral bone plate thickening, compared
to their WT siblings. Also, WT 129S2 mice that received DMM surgery followed by gefitinib
treatment (anti-EGFR antibody) showed milder OA damage in comparison to EgfrWa5/+ mice
(251). Furthermore, cartilage-specific (Col2-Cre) Egfr KO mice developed spontaneous OA
initiation with subchondral bone sclerosis at 12 months of age, earlier than WT mice (252).
Moreover, EGFR signaling enhances expression of Prg4 and hyaluronic acid (HA) at the cartilage
surface (250). Since both catabolic and anabolic activity of EGFR signaling in the joint has been
reported, it is strongly suggested that EGFR effects in articular cartilage are dose-and/or contextdependent, but the molecular mechanisms underlying these opposing roles are not understood.

1.4.2

Mitogen-Inducible Gene Mig-6 in development and joint pathology

First time described as a multi-hormonal inducible gene in 1985 by Kenney and colleagues, many
different factors have been reported to be responsible for the induction of Mig-6 (mitogeninducible gene 6) gene expression including hormones (insulin, glucocorticoids), cyclic adenosine
monophosphate (cAMP), phorbol esters and others (253). Moreover, growth factors (for example
EGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor/scatter factor (HGF/SF) and
TGFα) and many stresses conditions such as joint mechanical impact, hypoxia, diabetic
nephropathy, myocardial ischemic injury and infarction are also candidates to induce Mig-6 gene
expression (254). Mig-6 is a scaffolding adaptor protein involved in the regulation of the signaling
by EGFR. Mig-6 is also known as Gene 33, ErbB receptor feedback inhibitor 1 (ERRFI1), or as
receptor-associated late transducer (RALT) and is found in the cytosol of cells (255). Mig-6 is
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highly conserved in species such as Xenopus, rodent, and humans, but not in less in organisms
like S. cerevisae, C. elegans, or Drosophila (256). Mig-6 is differentially expressed in different
tissues and organs; for example, high levels of Mig-6 expression can be found in the liver and
kidney, however expression is also found in the placenta, heart, brain, skeletal muscle, stomach
and lung (257,258).Mig-6 gene has been linked to human lung cancer, such as in squamous cell
carcinoma patients, and late-stage patients with non-small cell lung cancer (NSCLC) (259).
Disruption of the MIG-6 gene can lead to bile duct, gastrointestinal (GI) tract, gallbladder, and
skin cancer (231,260).
Structurally, Mig-6 contains important protein-protein interactions domains/motifs, including a
Cdc42/Rac-interaction domain (responsible for regulators of actin cytoskeleton remodeling and
signal transduction) (256,261). The CRIB domain interacts with Cdc42, and the Src-homology-3
(SH3) domain binding motif interacts with Grb2 and 14-3-3 protein binding motifs. The carboxyl
terminus of Mig-6 has the ErbB-binding region (EBR) which connects to EGFR family receptors.
The EBR domain shares a homology with a non-receptor protein tyrosine kinase Ack-1, another
CRIB domain-containing protein that also interacts with EGFR (262–264). Mig-6 transcription is
induced by EGFR signaling at the transcriptional level (263,265). Mig-6 has been shown to block
the activation of EGFR induced signaling modules, such as the RAS-ERK and PI3K/AKT
pathways (265,266), as shown in Figure 1.4. Mig-6 can bind to and inhibit EGFR through a twotiered mechanism: suppression of EGFR catalytic activity and receptor down-regulation (267).
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Figure 1.4 Mitogen Inducible Gene 6 inhibits the activation of EGFR and RAS-ERK and
PI3K/AKT pathways. Canonical signaling pathways including PI3K-AKT and Ras-Raf-MEKERK that are involved in cell proliferation, gene expression and cell survival might be suppressed
in part by Mig-6.
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Figure 1.4 Mitogen Inducible Gene 6 inhibits the activation of EGFR and RAS-ERK and
PI3K/AKT pathways.

31
The Mig-6 protein includes two PEST sequences that can be targeted by ubiquitination and
degradation by the proteasome. Receptor endocytosis is an important mechanism by which
activated EGFR can be internalized, degraded or recycled, causing attenuation of EGFR activation.
Mig-6 can mediate this process. Moreover, Mig-6 binds to different proteins such as the cell
division control protein 42 homolog (Cdc42) (268) and c-Abl (269), in addition to all 4 EGFR
family receptors (ErbB1-4). Also, it is frequently suggested that Mig-6 is a part of a negative
feedback loop that diminishes HGF/Met (or c-Met) signalling, a ubiquitous pathway which
profoundly influences cell differentiation (64).
Therefore, it is quite possible that Mig-6 might participate or fine tune signal transduction via
different signaling pathways. Interestingly, various studies have reported that loss of Mig-6
induces the onset of OA-like symptoms (260,271–275). Global Mig-6-deficient mice showed
degradation of the articular cartilage and the formation of bony outgrowths due to proliferation of
mesenchymal-like progenitor cells followed by differentiation into chondrocytes. The most
affected joints are the knee, ankle and temporal-mandibular joints in which it is suggested that
mechanical stress could initiate this phenotype (271).
It has been shown that Mig-6 mRNA level were elevated in degenerating cartilage from a canine
model of mechanical impact on cartilage explants, however, down regulation of Mig-6 were
demonstrated followed induction of OA using a surgical rat model (272,276). The characterization
of cartilage-specific (Col2-Cre) knockout of Mig-6 mice showed formation of chondro-osseous
nodules, but also increased thickness of articular cartilage in the knee, ankle and elbow. Moreover,
the cartilage thickness was less pronounced at 36 weeks than in 12 week-old mice (277). Also,
limb mesenchyme-specific (Prx1-cre) knockout of Mig-6 resulted in a similar phenotype as that
observed in cartilage-specific knockout mice (277). These phenotypes appeared to be caused by
an increase in chondrocyte proliferation in articular cartilage, supported by increased expression
of Sox9 and EGFR activation in cartilage (278).
Recent studies by Staal et al (279) show that the deletion of Mig-6 results in the hyperactivation
of EGFR and histopathologically the mice showed formation of osteophyte-like nodules,
formation of subchondral cysts and cartilage degeneration in their knees. The overall effect of
Mig-6 signaling on OA development is determined by the balance of these two opposite actions
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of anabolic and catabolic effects and most likely is age‐, OA stage‐, and context‐dependent.
Understanding how Mig-6 exerts its function under different physiological conditions will provide
further insight into its potential roles in many cellular and biological processes, in particular in
synovial joints and OA.
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1.5

Overall Objectives and Hypotheses

Mitogen Inducible Gene 6 (Mig-6) and Epidermal growth factor receptor (EGFR) signaling have
been implicated in many different diseases such as cancer as well as osteoarthritis pathology. In
vivo and in vitro studies have shown that Mig-6/EGFR signaling and its ligands (EGF or TGFα)
play a dual role in cartilage homeostasis and degeneration. My general hypothesis is that regulation
of Mig-6/ EGFR is crucial for articular cartilage health.

1.5.1

Objective #1

To characterize the effects of cartilage-specific Mig-6 overexpression in mice using a cartilage
specific Mig-6 overexpressing mouse model.

1.5.1.1

Rationale #1

Previous research demonstrates that Mig-6 overexpression acts as a negative feedback regulator
of EGFR signaling, but these studies did not yet analyze joint tissues. Since our previous studies
suggest dosage- and/or context-specific roles of EGFR signalling in joint homeostasis and OA, we
will now examine whether overexpression of Mig-6 alters these processes.

1.5.1.2

Hypothesis #1

Mig-6 overexpression will block EGFR signalling and thus lead to spontaneous cartilage
breakdown and symptoms typical of OA.

1.5.2

Objective #2

To investigate the effects of skeletal-specific Mig-6 overexpression in the mouse limb
mesenchyme on primary OA development.

1.5.2.1

Rationale #2

We propose to elucidate the role of EGFR in this model using the paired-related homeobox gene
(Prx1) as Cre driver since it is more widely expressed in limb mesenchyme, including additional
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joint structures other than cartilage. We will now address the function of Mig-6 overexpression
mice in limb development and joint homeostasis in vivo.

1.5.2.2

Hypothesis #2

Mig-6 overexpression will decrease EGFR activity in the limb mesenchyme and will result in
catabolic cartilage damage.

1.5.3

Objective #3

To determine the effects of Mig-6 overexpression on post-traumatic OA.

1.5.3.1

Rationale #3

Based on our in vivo data showing cartilage damage in aging Mig-6 overexpressing mice, we asked
whether cartilage specific Mig-6 overexpression would protect or not from cartilage degeneration
in osteoarthritis following surgical destabilization of medial meniscus (DMM), which is the most
accepted surgical OA model in mice.

1.5.3.2

Hypothesis #3

Cartilage specific overexpression of Mig-6 will accelerate progression of post-traumatic OA.
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2.1 Abstract
Background: Osteoarthritis (OA) is the most common form of arthritis and characterised by
degeneration of articular cartilage. Mitogen-inducible gene 6 (Mig-6) has been identified as a
negative regulator of the Epidermal Growth Factor Receptor (EGFR). Cartilage-specific Mig-6
knockout (KO) mice display increased EGFR signaling, an anabolic buildup of articular cartilage
and formation of chondro-osseous nodules. Since our understanding of the EGFR/Mig-6 network
in cartilage remains incomplete, we characterised mice with cartilage-specific overexpression of
Mig-6 in this study.
Methods: Utilizing knee joints from cartilage-specific Mig-6 overexpressing (Mig-6over/over) mice
(at

multiple

time

points),

we

evaluated

the

articular

cartilage

using

histology,

immunohistochemical staining and semi-quantitative OARSI scoring at multiple ages. MicroCT
analysis was employed to examine skeletal morphometry, body composition, and bone mineral
density.
Results: Our data show that cartilage-specific Mig-6 overexpression did not cause any major
developmental abnormalities in articular cartilage, although Mig-6over/over mice have slightly
shorter long bones compared to the control group. Moreover, there was no significant difference
in bone mineral density and body composition in any of the groups. However, our results indicate
that Mig-6over/over male mice show accelerated cartilage degeneration at 12 and 18 months of age.
Immunohistochemistry for SOX9 demonstrated that the number of positively stained cells in Mig6over/over mice decreased relative to controls. Immunostaining for MMP13 staining is increased in
areas of cartilage degeneration in Mig-6over/over mice. Moreover, staining for phospho-EGFR (Tyr1173) and lubricin (PRG4) was decreased in the articular cartilage of Mig-6over/over mice.
Conclusion: Overexpression of Mig-6 in articular cartilage causes no major developmental
phenotype; however, these mice develop earlier OA during aging than control mice. These data
demonstrate that Mig-6/EGFR pathways is critical for joint homeostasis and might present a
promising therapeutic target for OA.
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2.2

Introduction

Osteoarthritis (OA), a chronic degenerative joint disease, is the most common form of arthritis.
OA affects nearly five million Canadians currently (1), but that number will grow to more than 10
million by 2040 (2). This statistic is alarming, considering the disability, the loss of quality of life,
and the costs to the health system generated by OA. Currently, there are pharmacological
treatments available to manage OA symptoms such as pain (3–5) as well as surgical joint
replacement at the end stage of disease (6,7). Unfortunately, however, there is no known cure for
OA. Progressive understanding of the pathophysiology of OA suggests that the disease is a
heterogeneous condition, so further research is needed to direct the clinical approaches to disease
management (8).
Recent studies have shown that OA is a multifactorial disease of the whole joint, however its
pathogenesis remains still poorly understood (9). Genetic, environmental, and biomechanical
factors can accelerate the onset of OA (10). Articular cartilage is a highly specialized tissue that
forms the smooth gliding surface of synovial joints, with chondrocytes as the only cellular
component of cartilage (11). The homeostasis of the cartilage extracellular matrix (ECM) involves
a dynamic equilibrium between anabolic and catabolic pathways controlled by chondrocytes (12).
The progression of OA is associated with dramatic alteration in the integrity of the cartilage ECM
network formed by a large number of proteoglycans (mostly aggrecan), collagen II, and other noncollagenous matrix proteins (13). In addition, ECM synthesis is regulated by a number of
transcriptional regulators involved in chondrogenesis, specifically Sex- determining- region-Y
Box 9 (SOX9), L-SOX 5 and SOX6 that regulate type II collagen (Col2a1) and Aggrecan (Acan)
gene expression (14). On the other hand, catabolic events are dominant in OA and cells are exposed
to degenerative enzymes such as aggrecanases (e.g. ADAMTS-4, -5) (13,15), collagenases (e.g.
MMP-1,-3, -8, -13) (16), and gelatinases (e.g.MMP-2, and MMP-9), all of which have implications
in articular cartilage degeneration (17). A number of growth factors (18) play a role in OA
pathology, such as transforming growth factor-β (19), BMP-2 (20), Insulin growth factor 1 (IGF1) (21) fibroblast growth factor (FGF) and others, but the exact regulation of chondrocyte
physiology is still not completely understood.
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Recent studies in our laboratory (22,23) have identified the epidermal growth factor receptor
(EGFR) and its ligand transforming growth factor alpha (TGFα) as possible mediators of cartilage
degeneration (24–26). The human TGFA gene locus was also strongly linked to hip OA and
cartilage thickness in genome-wide association studies (27,28). TGFα stimulates EGFR signaling
and activates various cell-signaling pathways in chondrocytes, including extracellular signalregulated kinase 1 and 2 (ERK1/2) and P13K (phosphoinositide 3-kinase) (29). EGFR signaling
plays important roles in endochondral ossification (30,31), growth plate development (30) and
cartilage maintenance and homeostasis (32–34), but many aspects of its action in cartilage are still
not well understood. However, both protective and catabolic effects of EGFR signaling in OA
have been reported, suggesting context-specific roles of this pathway (35).
Mitogen-inducible gene 6 (Mig-6) is also known as Gene 33, ErbB receptor feedback inhibitor 1
(ERRFI1), or RALT, and is found in the cytosol (36). Mig-6 protein binds to and inhibits EGFR
signaling through a two-tiered mechanism: suppression of EGFR catalytic activity and receptor
down-regulation (37). Interestingly, various studies have reported that loss of Mig-6 induces the
onset of OA-like symptoms in mice (36,38–40). Cartilage-specific (Col2-Cre) knockout of Mig-6
mice results in formation of chondro-osseous nodules in the knee, but also increased thickness of
articular cartilage in the knee, ankle, and elbow (41). Prx1-cre-mediated knockout of Mig-6 results
in a similar phenotype as that observed in cartilage-specific knockout mice(42). These phenotypes
appeared to be caused by an increase in chondrocyte proliferation in articular cartilage, supported
by increased expression of Sox9 and EGFR activation in cartilage (42). Since our studies suggest
dosage- and/or context-specific roles of EGFR signaling in the process of cartilage degeneration
in OA, in this study we used a Col2a1 promoter–driven Cre/lox system to examine effects of Mig6 overexpression specifically in articular cartilage.

2.3
2.3.1

Materials and Methods
Generation of Mig-6 overexpression mice

Mig-6 overexpression animals on a mixed C57Bl/6 and agouti mouse background, with the
overexpression cassette in the Rosa26 locus (43) and bred for 10 generations into a C57Bl/6
background. Transcription of Mig-6 is under the control of a ubiquitously expressed chicken beta
actin-cytomegalovirus hybrid (CAGGS) promoter, but blocked by a “Stop Cassette” flanked by
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LoxP sites (LSL) (43). Mig-6 overexpression mice were bred to mice carrying the Cre recombinase
gene under the control of the Collagen 2 promoter (44), to induce recombination and removal of
the STOP Cassette specifically in cartilage. Throughout the manuscript, animals for homozygote
overexpression of Mig-6 from both alleles are termed Mig-6 over/over (Mig-6 over/overCol2a1-Cre+/-),
while control mice are identical but without the Cre gene (noted as “control” in this manuscript for
simplicity). Mice were group housed (at least 1 pair of littermate-matched control and
overexpression animals), on a standard 12-hour light/dark cycle, without access to running wheels,
and with free access to mouse chow and water. Animals were weighed prior to euthanization by
asphyxiation with CO2. All animal experiments were done in accordance with the Animal Use
Subcommittee at the University of Western Ontario and conducted in accordance with guidelines
from the Canadian Council on Animal Care.

2.3.2

Genotyping

Genotype was determined by polymerase chain reaction (PCR) analysis using DNA processed
from biopsy samples of ear tissue from mice surviving to at least 21 days of age. PCR strategy:
Primer set P1 and P2 can amplify a 300 bp fragment from the wild-type allele, whereas P1 and P3
can amplify a 450 bp fragment from the targeted ROSA26 locus allele (43) (Supp. Figure/Table
1).

2.3.3

RNA isolation and Quantitative real-time PCR

Total RNA was isolated from post-natal day 0 (P0) mouse cartilage of Mig-6 over/over and control
littermates using TRIzol® (Invitrogen) as per manufacturer’s instructions and as previously
described (45). Complementary DNA (cDNA) was synthesized using the iScript cDNA Synthesis
kit (Bio-Rad) with 1µg of RNA (Bio-Rad Laboratories), and combined with 300nM of forward
and reverse primers (for primer sequences, please see Supplementary Table 1) as well as iQ™
SYBR® Green Supermix (Bio-Rad Laboratories) for PCR on a Bio-Rad CFX384 RT-PCR system.
(Supp. Figure/Table 1).

Relative gene expression was normalized to the internal control

Glyceraldehyde 3-phosphate dehydrogenase (Gapdh), calculated using the ΔΔCT method.

2.3.4

Histopathology of the knee

Limbs from Mig-6

over/over

and control mice were harvested and fixed in 4% paraformaldehyde
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(Sigma) for 24 hours and decalcified in ethylenediaminetetraacetic acid (5% EDTA in phosphate
buffered saline (PBS), pH 7.0. Joints were processed and embedded in paraffin in sagittal or
frontal orientation, with serial sections taken at a thickness of 5 μm. Sections were stained with
Toluidine Blue (0.04% toluidine blue in 0.2M acetate buffer, pH 4.0, for 10 minutes) for
glycosaminoglycan content and general evaluation of articular cartilage. All images were taken
with a Leica DFC295 digital camera and a Leica DM1000 microscope.

2.3.5

Thickness of proximal tibia growth plate

For early developmental time points such as newborn (P0), sagittal knee sections stained with
toluidine blue were used to measure the width of the zones of the epiphyseal growth plate in the
proximal tibia. The average thickness of the resting and proliferative zones combined was
evaluated by taking three separate measurements at approximately equal intervals across the width
of the growth plate. The average hypertrophic zone thickness was also measured using 3 different
measurements across the width of the growth plate, starting each measurement at the border of the
proliferative and hypertrophic zones and ending at the subchondral bone interface. A third average
measurement was then taken of the thickness of the entire growth plate. ImageJ Software (v.1.51)
(46) was used for all measures, with the observer blinded to the genotype.

2.3.6

Articular cartilage evaluation

Articular cartilage thickness was measured from toluidine blue-stained frontal sections by a
blinded observer. Articular cartilage thickness was measured separately for the non-calcified
articular cartilage (measured from the superficial tangential zone to the tidemark) and the calcified
articular cartilage (measured from the subchondral bone to the tidemark) across three evenly
spaced points from all four quadrant of the joint (medial/lateral tibia and femur) in 4 sections
spanning at least 500 μm. ImageJ Software (v.1.51) (46) was used to measure the thickness of
articular cartilage.

2.3.7

Micro-Computerized Tomography (μCT)

Whole body scans were collected in 6 week-, 11 week-, 12 month-, and 18-month-old control and
Mig-6

over/over

male and female mice. Mice were euthanized and imaged using General Electric

(GE) SpeCZT microCT machine (47) at a resolution of 50μm/voxel or 100μm/voxel. GE
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Healthcare MicroView software (v2.2) was used to generate 2D maximum intensity projection and
3D isosurface images to evaluate skeletal morphology. MicroView was used to create a line
measurement tool in order to calculate the bone lengths, femurs lengths were calculated from the
proximal point of the greater trochanter to the base of the lateral femoral condyle. Tibiae lengths
were measured from the midpoint medial plateau to the medial malleolus. Humerus lengths were
measured from the midpoint of the greater tubercle to the center of the olecranon fossa.

2.3.8

Body Composition Analysis

MicroView software (GE Healthcare Biosciences) was used to analyse the microCT scans at the
resolution of 100um/voxel. Briefly, the region of interest (ROI) was used to calculate the mean of
air, water and an epoxy-based, cortical bone-mimicking calibrator (SB3; Gammex, Middleton, WI,
USA) (1100mg/cm3) (48). A different set of global thresholds was applied to measure adipose,
lean and skeletal mass (− 275, − 40 and 280 Hounsfield Units (HU), respectively). Moreover, bone
mineral density (BMD) was acquired as the ratio of the average HU (from the value of skeletal
region of interest ) in order to calculate HU value of the SB3 calibrator, multiplied by the known
density of the SB3 as described (47).

2.3.9

OARSI histopathology scoring

Serial sections through the entire knee joint were scored according to the OARSI histopathology
scoring system (49) by two blinded observers on the four quadrants of the knee: lateral femoral
condyle (LFC), lateral tibial plateau (LTP), medial femoral condyle (MFC), and medial tibial
plateau (MTP). Histologic scoring from 0-6 represent the OA severity, from 0 (healthy cartilage)
to 6 (erosion of more than 75% of articular cartilage). Individual scores are averaged across
observers and OA severity is shown as described for each graph. Scores were compared between
male and female Mig-6 over/over and control mice at both 12 and 18 months of age. All images were
taken with a Leica DFC295 digital camera and a Leica DM1000 microscope.

2.3.10 Immunohistochemistry
Frontal paraffin sections of knees were used to for immunohistochemical analysis, with slides with
‘no primary antibody’ as control. All sections were deparaffinized and rehydrated as previously
described (41,50). Subsequently, the sections were incubated in 3% H2O2 in methanol for 15
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minutes to inhibit endogenous peroxidase activity. After rising with water, 5% goat or donkey
serum in PBS was applied to reduce nonspecific background staining. Sections were incubated
overnight at 4°C with primary antibodies against SOX9 (R&D Systems, AF3075), MMP13
(Protein Tech, Chicago, IL, USA, 18165-1-AP), lubricin (Abcam, ab28484) and phospho-EGFR
(phosphoTyr-1173; Cell Signaling Technology). After washing, sections were incubated with
horseradish peroxidase (HRP)-conjugated donkey anti-goat or goat anti-rabbit secondary antibody
(R&D system and Santa Cruz), before incubation with diaminobenzidine substrate as a chromogen
(Dako, Canada). Finally, sections were counterstained with 0.5% methyl green (Sigma) and
mounted. Cell density of articular cartilage chondrocytes from 6 and 11 weeks-old male mice was
determined by counting all lacunae with evidence of nuclear staining in the lateral and medial
femur/tibia using a centered region of interest measuring 200 μm wide and 70 μm deep from the
articular surface by a blinded observer. For newborn (P0) animals the region of interest measured
200 μm wide and 100 μm deep from the proliferative zone.

2.3.11 Statistical Analysis
All statistical analyses were performed using GraphPad Prism (v6.0). Differences between two
groups were evaluated using Student's t-test, and Two-Way ANOVA was used to compare 4
groups followed by a Bonferroni multiple comparisons test. All n values represent the number of
mice used in each group/genotyping.

2.4
2.4.1

Results
Overexpression of Mig-6 has minor effects on skeletal phenotypes during
development

We bred mice for conditional overexpression of Mig-6 (43) to mice expressing Cre recombinase
under control of the collagen II promoter. Homozygote mice overexpressed Mig-6 in all collagen
II-producing cells (and their progeny) from both Rosa26 alleles and are referred to as Mig-6 over/over
from here on. Control mice do not express Cre. Genomic DNA was extracted from ear notches to
identify homozygous mice Mig-6over/overusing standard PCR analysis. Overexpressing mice were
obtained at the expected Mendelian ratios (data not shown). Male mutant gained weight at the
same rate as controls over the examined at 10-week period, while female Mig-6over/over mice were
slightly lighter than controls starting at 8 weeks of age (Fig. 2.1A, B). These differences persisted
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at 12 months of age for female mice, while at 18 months both male and female mutant mice were
lighter than their controls (Fig. 2.1C, D). Growth plates of post-natal day 0 (P0) Mig-6 over/over and
control mice were analyzed by histology. No major differences in tibia growth plate architecture
were seen between genotypes (Fig. 2.2A). While the length of the total growth plate was slightly
reduced in Mig-6 over/over mice, differences in lengths of either the combined resting/proliferative
or hypertrophic zones were not statistically significant (Fig. 2.2B-D).
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Figure 2.1 Body weight of control and Mig-6over/over male and female mice during growth.Body
weight of male Mig-6 overexpression mice did not show any significant differences compared to
control (A) Female Mig-6 overexpression mice showed statistically significant differences
compared to control at 8w, 9w and 10w (B). Two-Way ANOVA was used with Bonferroni post
hoc analysis (n=5/genotyping). Data are presented with mean and error ± SEM (P<0.05). Weights
of 12 months old (C) and 18 months old (D) male and female cartilage specific Mig-6over/over mice
and controls taken immediately prior to sacrifice. Individual data points presented with mean ±
SEM (P<0.05). Data analyzed by two tailed student t-tests from 6-12 mice per group
(age/genotyping).
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Figure 2.1. Body weight of control and Mig-6over/over male and female mice during growth
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Figure 2.2 Cartilage-specific Mig6-overexpressing mice display no major developmental
phenotype. Representative toluidine Blue staining on postnatal day 0 (P0) of Mig-6over/over (A)
and control animals. Thickness of total proximal tibia growth plates in the mice containing
articular cartilage specific mitogen inducible gene 6 overexpression (n=6), when compared to age
matched controls (n=6) was significantly decreased when analyzed by two tailed student t-tests
(B); The average of hypertrophic zone thickness from postnatal day 0 in the mice containing
articular cartilage specific mitogen inducible gene 6 overexpression had mean of 188.9 µm and
control mice had mean of 184.4 µm (C). The thickness of the combined resting and proliferative
zones from the control had mean of 728 µm and Mig-6over/over 706.5 µm Mig-6over/over(D).
Therefore, there was no significant differences within the groups. Individual data points presented
with mean ± SEM analyzed by two tailed student t-tests; (P<0.05).
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Figure 2.2 Cartilage-specific Mig6-overexpressing mice display no major developmental
phenotype
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2.4.2

Mice overexpressing Mig-6 have shorter long bones than control mice

Skeletal morphology and bone length were examined by microCT mice at the ages of 6 and weeks,
and 12 and 18 months. Scans of Mig-6 over/over male and female mice and their controls were used
to generate 3D isosurface reconstructions of 100μm/voxel uCT scans, in order to measure long
bones lengths (femurs, humeri, and tibiae) in GE MicroView v2.2 software. Mutant bones were
slightly shorter throughout life, with the exception of the male humeri at 12 months that did not
show any statistically significant difference (Fig. 2.3). In contrast, male mice did not show any
differences in bone mineral density at 11 weeks, 12 months, or 18 months, compared to controls
(Suppl. Fig. 2). In addition, no differences in body mass composition were seen in male mutant
and control mice at 11 weeks, 12 months, and 18 months of age (Suppl. Fig. 3).
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Figure 2.3 Long bone lengths of Mig-6 overexpression are significantly shorter than control
long bone lengths during growth and aging. The lengths of right humeri, tibiae and femora were
measured on microCT scan of mice in each different time-points of age using GE MicroView
software. (A) 6 weeks-old male and female control and Mig-6 overexpressors. (B) 11 weeks-old
male and female control and Mig-6 overexpressors. (C) 12 months-old male and female control
and Mig-6 overexpressors. (D) 18 months-old male and female control and Mig-6 overexpressors.
(A1) Representative 3D isosurface reconstructions of 100μm/voxel µCT scans. There were
statistically significant differences among control and Mig-6over/over male and female groups.
Individual data points presented with mean ± SEM (P<0.05). Data analyzed by two tailed student
t-tests from 6-12 mice per group (age/gender).

70

71

Figure 2.3 Long bone lengths of Mig-6 overexpression are significantly shorter than control long
bone lengths during growth and aging
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2.4.3

Mig-6 overexpressing mice have healthy articular cartilage during skeletal
maturity

We next examined articular cartilage morphology in 11-week-old mutant and control mice using
toluidine blue stained paraffin frontal knee sections (Fig. 2.4A-B). The average thickness of the
calcified articular cartilage and non-calcified articular cartilage in the lateral femoral condyle
(LFC), lateral tibial plateau (LTP), medial femoral condyle (MFC), and medial tibial plateau
(MTP) from control and Mig-6 over/over male (Fig. 2.4C-D) and female (Suppl. Fig. 4A-D) mice
did not show statistically significant differences. Histological analyses of knee sections from male
and female mice did not show any loss of proteoglycan, fibrillation or erosion in the articular
cartilage of mutant mice.
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Figure 2.4 Articular cartilage from 11 weeks-old Mig-6over/over male mice appeared healthy
during skeletal maturity. Representative (n=5/group, toluidine blue) stained frontal sections of
knee joints from 11-week-old control (A) and Mig-6over (B). Mig-6 overexpressors mice show
similar articular cartilage thickness when compared to controls at 11 weeks-old male mice. The
average thickness of the calcified articular cartilage (C) and non-calcified articular cartilage (D)
in the lateral femoral condyle (LFC), lateral tibial plateau (LTP), medial femoral condyle (MFC),
medial tibial plateau (MTP) was measured. Individual data points presented with mean ± SEM.
Data analyzed by two-way ANOVA (95% CI) with Bonferroni post-hoc test. Scale bar = 100µm.
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Figure 2.4 Articular cartilage from 11 weeks-old Mig-6over/over male mice appeared healthy
during skeletal maturity
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2.4.4

Overexpression of Mig-6 in cartilage induces an osteoarthritis-like
phenotype in mice during aging

Since aging is a primary risk factor in OA (51), we next examined knee joints in 12 and 18 monthold control and Mig-6 over/over mice. Toluidine blue stained sections were evaluated by two blinded
observers, using OARSI recommendations (49). At 12 month of age, male control mice showed
minor signs of cartilage damage, such as loss of proteoglycan staining, but no significant structural
degeneration (Fig. 2.5A). However, seven of nine Mig-6 over/over male mice showed more extensive
cartilage damage in their medial side (erosion to the calcified layer lesion for 25% to 50% of the
medial quadrant). OARSI scoring confirmed increased OA-like damage in mutant mice (Fig.
2.5C). Similarly, at 18 months of age the male control group showed minimal cartilage
degeneration in 3 of 6 mice (Fig. 2.6A). Mig-6 over/over male mice showed more severe cartilage
erosion in the medial tibial plateau in 4/6 animals. This result was again supported by significantly
increased OARSI cartilage damage scores (Fig. 2.6C). Moreover, for the female group at 12
months, control mice did not show cartilage damage in any quadrant of the knee. Mig-6 over/over
female mice showed sign of OA-like cartilage damage in 3/8 animals (Supplementary Fig. 5). In
addition, at 18 months of age, female control mice showed healthy cartilage, and 4/8 Mig-6 over/over
female mice showed some proteoglycan loss and cartilage degeneration on the medial side (Suppl.
Fig. 6).
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Figure 2.5 12 months old Mig-6over/over male mice develop OA-like cartilage degeneration.
Representative images of Toluidine Blue stained sections of knee joints from 12-month male
control (A) and male Mig-6 over (B) mice were evaluated for cartilage damage following OARSI
histopathological scale on the two quadrants of the knee: MFC = medial femoral condyle, MTP =
medial tibial plateau. OARSI based cartilage degeneration scores are significantly higher in the
MFC and MTP of Mig-6 overexpressing mice, corresponding to the increased damage observed
histologically (C). Data analyzed by two-way ANOVA with Bonferroni's multiple comparisons
test. Individual data points presented with mean ± SEM. All scale bars =100 μm. N = 9 mice/group.
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Figure 2.5 12 months old Mig-6over/over male mice develop OA-like cartilage degeneration
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Figure 2.6 18 months old Mig-6over/over mice leads to advanced OA-like cartilage.
Representative images of Toluidine Blue stained sections of knee joints from 18-month male
control (A) and male Mig-6 over (B) mice were evaluated for cartilage damage following OARSI
histopathological scale on the two quadrants of the knee: MFC = medial femoral condyle, MTP =
medial tibial plateau. OARSI based cartilage degeneration scores are higher both in the MFC and
MTP of Mig-6 overexpressing mice, corresponding to the increased damage observed
histologically. (C) Data analyzed by two-way ANOVA with Bonferroni's multiple comparisons
test. Individual data points presented with mean ± SEM. All scale bars =100 μm. N = 6 mice/group.
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Figure 2.6 18 months old Mig-6over/over mice leads to advanced OA-like cartilage
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2.4.5

Overexpression of Mig-6 decreases EGFR phosphorylation and Sox9
expression

Since Mig-6 negatively regulates EGFR signaling (32,33,41), immunohistochemistry was
performed for phospho-EGFR (Tyr-1173) (pEGFR), with no primary antibody controls. Frontal
knee sections from 11 weeks-old male Mig-6 over/over mice showed decreased pEGFR staining in
the medial compartment in the knee joint (Fig.7), as expected upon Mig-6 overexpression. During
chondrogenesis, the transcription factor SOX9 is required for cartilage formation and normal
expression of collagen and aggrecan (52). Sagittal and frontal sections of paraffin embedded knees
from post-natal day 0 (P0), 6 weeks-old, 11 weeks-old, 12 months and 18 months male mice were
used for SOX9 immunostaining. At P0, nuclear SOX9 expression was observed in the resting and
proliferative zone of the growth plate in both genotypes (Fig. 2.8A, B). Cell density was not
different between genotypes (Fig. 8C). In control mice, 78 % of chondrocytes were positive for
SOX 9 immunostaining, while the proportion of positive cells was only 53 % in Mig-6 over/over mice
(Fig 2.8D). In 6 and 11-weeks-old mice, SOX9 was present in the articular cartilage in all four
quadrants (Fig. 2.9A, B). At 6 weeks-old the total cell number in control male and Mig-6over/over
mice is similar (Fig. 2.9C), but the percentage of SOX9 positive cells was decreased in mutant
mice (Fig 2.9D). A similar phenotype was present at 11 weeks (Supplementary Fig 7). At 12
months of age, SOX9 is present more in the lateral side (LTP and LFC) than the medial side (MTP
and MFC) in both strains, with a few positive cells present in the medial side of the control strain.
On the other hand, Mig-6 over/over mice showed fewer SOX9-positive cells on the medial side due
the articular cartilage damage (Fig 2.10). Similar results were found at 18 months of age in Mig-6
over/over

with decreased SOX9 immunostaining in their medial side compared to the control (data

not shown). For all ages, negative controls did not show staining in chondrocytes.
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Figure 2.7 Phospho-EGFR staining is decreased in the articular cartilage of cartilage specific
Mig-6 overexpressing mice at 11 weeks of age. Immunostaining of phosphorylated epidermal
growth factor receptor (pEGFR; Tyr-1173) in the knee joints of 11-week-old Mig-6 over/overCol2a1Cre+/- (B) is decreased in response to increased Mig-6 levels. Frontal sections of mice articular
cartilage, as negative control, exhibited no staining (C). Also, cartilage-specific deletion of Mig6, serving as positive control (D). N=5 mice/genotyping. MFC = medial femoral condyle and MTP
= medial tibial plateau. Scale bar = 100µm.
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Figure 2.7 Phospho-EGFR staining is decreased in the articular cartilage of cartilage specific
Mig-6 overexpressing mice at 11 weeks of age

83

Figure 2.8 SOX9 immunostaining shows a decrease in Mig-6 overexpressors mice at postnatal day 0 (p0). Ratio between the total cell number from control and Mig-6over/over (B).
Ratio between the percentage of Sox9 positive cells from control and Mig-6over/over at p0 mice (C).
Data analyzed by two tailed student t-tests from 5 mice per group. Individual data points presented
with mean ± SEM (P<0.05). Scale bar = 100µm.
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Figure 2.8 SOX9 immunostaining shows a decrease in Mig-6 overexpressors mice at post-natal
day 0 (p0)
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Figure 2.9 SOX9 immunostaining shows a decrease in Mig-6 overexpressors mice at 6 weeksold male mice control and Mig-6over/over. No primary antibody for SOX9 display no staining with
methyl green counterstain in mice. Ratio between the total cell number from control and Mig6over/over at 6 weeks-old male mice (C). Ratio between the percentage of Sox9 positive cells from
control and Mig-6over at 6 weeks-old male mice (D). Data analyzed by two-way ANOVA
(95% CI) with Bonferroni post-hoc test. Individual data points presented with mean ± SEM; N= 5
mice/genotyping. LFC = lateral femoral condyle, LTP = lateral tibial plateau, MFC = medial
femoral condyle and MTP = medial tibial plateau. Scale bar = 100µm.
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Figure 2.9 SOX9 immunostaining shows a decrease in Mig-6 overexpressors mice at 6 weeksold male mice control and Mig-6over/over
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Figure 2.10 12-month-old cartilage specific Mig-6 overexpressing mice show decreased
SOX9 immunostaining. Representative SOX9 immunostained in male mice (n=5) in MFC and
MTP show decreased staining intensity in Mig-6 over mice (B) when compared to control (A). No
primary control for articular cartilage (C). LFC = lateral femoral condyle, LTP = lateral tibial
plateau, MFC = medial femoral condyle and MTP = medial tibial plateau. Scale bar = 100µm.
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Figure 2.10 12-month-old cartilage specific Mig-6 overexpressing mice show decreased SOX9
immunostaining
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2.4.6

Overexpression of Mig-6 decreases expression of lubricin

Lubricin (aka PRG4/superficial zone protein) is a proteoglycan that plays an important role as
lubricant in the joint (53). EGFR signaling is crucial for the cartilage lubrication function and
regulates the induction of Prg4 expression which is necessary for smooth movement (33,54).
Immunohistochemistry for Lubricin in 11-week-old and 12 months-old animals demonstrated less
staining in the superficial zone of the medial side of Mig-6 over/over mice than in the control group
(Fig. 2.11 and Fig. 2.12).
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Figure 2.11 Lubricin immunostaining is slightly decreased in the articular cartilage of
cartilage specific Mig-6 overexpressing mice at 11 weeks of age. Immunostaining of sections
of the knee joint indicate the presence of Lubricin (PRG4) in the superficial zone chondrocytes.
IHC reveals no staining for the negative control (C) and Mig-6 KO, serving as positive control
(D). N=4-5 mice/genotyping. MFC = medial femoral condyle and MTP = medial tibial plateau.
Scale bar = 100µm.
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Figure 2.11 Lubricin immunostaining is slightly decreased in the articular cartilage of cartilage
specific Mig-6 overexpressing mice at 11 weeks of age
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Figure 2.12 Lubricin immunostaining is decreased in the articular cartilage of cartilage
specific Mig-6 overexpressing mice at 12 months of age. Immunostaining of sections of the
knee joint indicate the presence of Lubricin (PRG4) in the superficial zone chondrocytes. N=4-5
mice/genotyping. MFC = medial femoral condyle and MTP = medial tibial plateau. Scale bar =
100µm.
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Figure 2.12 Lubricin immunostaining is decreased in the articular cartilage of cartilage specific
Mig-6 overexpressing mice at 12 months of age
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2.4.7

MMP13 immunostaining is increased in Mig-6-overexpressing and control
mice

Matrix metalloproteinase (MMP) 13 is highly expressed in OA (55,56). Frontal sections of knees
from 12- and 18-month-old control and Mig-6

over/over

male mice were used for MMP13

immunohistochemistry. At 12 months, pericellular staining was observed in the lateral articular
cartilage of male mice from both genotypes, along with the expected subchondral bone staining
(Fig. 2.13). Immunostaining for MMP13 on serial sections of lesions revealed strong staining in
the same areas of cartilage degeneration in mutant mice than control mice. Negative controls did
not show staining in cartilage or subchondral bone. Articular cartilage from 18 months-old mice
showed similar staining patterns and intensity of MMP13 immunostaining in the lateral side of
both genotypes, however in the medial side of Mig-6 over/over mice, MMP13 staining is seen on the
cartilage surface (lesion sites) and also observed in the subchondral bone (data not shown).
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Figure 2.13 12-month-old cartilage specific Mig-6 overexpressing mice show similar pattern
of MMP13 as the control mice. Representative immunohistochemistry of matrix
metalloproteinase 13 (MMP13) for Mig-6 overexpression mice at 12 months control (A) and
cartilage specific Mig-6 overexpression (B). No primary control for articular cartilage (C). N=5
mice/genotyping. LFC = lateral femoral condyle, LTP = lateral tibial plateau, MFC = medial
femoral condyle and MTP = medial tibial plateau. Scale bar = 100µm.
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Figure 2.13 12 month-old cartilage specific Mig-6 overexpressing mice show similar pattern of
MMP13 as the control mice
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2.5

Discussion

The maintenance of articular cartilage homeostasis relies on a dynamic equilibrium involving
growth factors (57), genetics (58), mechanical forces (59), obesity and injury, that all play a role
in the onset of osteoarthritis (60). Better understanding of the underlying molecular mechanism is
required to design therapies for preventing progression of OA. Recent studies from our laboratory
and others have identified the epidermal growth factor receptor (EGFR) and Mig-6 as possible
mediators of articular cartilage homeostasis (35,41,54,61). Mig-6 is a cytosolic protein and
negative feedback regulator of EGFR signalling (62); thus, Mig-6 can be a potential tumor
suppressor (43,63–66). In addition, whole body knockout of the Mig-6 gene in mice results in
degenerative joint disease (38). We also have shown previously that constitutive cartilage-specific
deletion of Mig-6 (Mig-6 KO) results in increased articular cartilage thickness and cell density in
the joints of 12 week-old mice (41). Cartilage-specific Mig-6 KO mice show the same anabolic
effect in joint cartilage at 21 months of age (unpublished).
Previous research demonstrates that Mig-6 overexpression acts as a negative feedback regulator
of EGFR-ERK signalling (43), however these studies did not yet analyze joint tissues. Since our
studies suggest dosage- and/or context-specific roles of EGFR signaling in joint homeostasis and
OA (35), we now examined whether overexpression of Mig-6 alters these processes. Here, we
report that cartilage-specific constitutive overexpression of Mig-6 did not cause cartilage
degeneration in young mice, but early onset OA in middle aged mice. While we observed some
effects of Mig-6 overexpression on bone length and weight, these effects were subtle and not
accompanied by major morphological or histological changes in growth plate cartilage, overall
skeletal morphology, or body composition. A previous study showed that deletion of EGFR in
bone tissue (Col1-Cre EgfrWa5/f ) resulted in shorter femurs compared to wild-type mice (67),
consistent with our findings. The EGFR network is essential during long bone development, since
previous studies have shown that EGFR- or TGF-deficient mice exhibit a widened zone of
hypertrophic chondrocytes (24,68). Moreover, Qin and colleagues have shown that administration
of the EGFR inhibitor, gefitinib, into 1-monht-old rats results in an enlarged hypertrophic zone
due down-regulation of MMP-9,-13 and -14 (31). Together these data suggest a critical role of
EGFR during endochondral ossification and elucidate downstream mechanism of EGFR (69).
Further research is required to provide more evidence of EGFR/Mig-6over/over signalling during
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bone formation, but many of these effects are relatively subtle and transient, and likely unrelated
to much more severe phenotypes observed later.
Histologically, our findings showed that mice with cartilage-specific Mig-6 overexpressing
showed healthy articular cartilage with no significant difference in articular cartilage thickness
from control group at the ages of 6 weeks and 11 weeks. However, Mig-6 over/over mice developed
severe degeneration of articular cartilage with aging. More prevalent, the knee joints of Mig-6
over/over

male mice showed significantly advanced cartilage degeneration. The same pattern but with

more severe damage, was seen in 18-month-old mice. As previously described, sex hormones play
a role in OA disease where male mice develop more severe OA (70).
SOX9 is crucial in chondrogenesis during endochondral bone formation, articular cartilage
development and cartilage homeostasis (52). Previous in vivo models using cartilage (Col2)-Cre
or limb (Prx1)-Cre specific ablation of Mig-6 showed increased expression of SOX9 in the
articular cartilage. Also, TGFα supresses expression of anabolic genes such as Sox9, type II
collagen and aggrecan in primary chondrocytes (71). Interestingly, in the medial and lateral
compartment of the knee joints of 6 and 11-week-old male Mig-6 over/over mice, the percentage of
SOX9- positive chondrocytes was decreased compared to controls, despite the absence of
histological defects in articular cartilage. These data suggest that reduced number of Sox9expressing cells precede the degeneration of articular chondrocytes in our mutant mice. The
number of SOX9-expressing cells was also reduced in Mig-6 over/over mice at later ages. These data
suggest that reduced numbers of Sox9-expressing cells could be one cause of the advanced OA in
our mutant mice. In addition, we observed decreased expression of lubricin/PRG4 in these joints,
which might also contribute to the observed joint pathologies. PRG4 has been shown to be
regulated by EGFR signaling before (42,54), in support of our findings.
While the EGFR is the best characterised substrate of Mig-6, other substrates have been described.
Mig-6 binds to different proteins such as the cell division control protein 42 homolog (Cdc42)
(72), c-Abl (73), and the hepatocyte growth factor receptor c-Met (74). While we cannot exclude
that deregulation of these other substrates contributes to the observed phenotypes, the similarities
of defects in our mice with those seen upon cartilage-specific deletion of EGFR suggest that
decreased EGFR signaling is the main cause for the advanced OA observed in our mutant mice.
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Nevertheless, it will be important to determine whether signaling through cMet and other pathways
is altered as well.
In conclusion, we show for the first time that cartilage-specific Mig-6 overexpression in mice
results in reduced EGFR activity in chondrocytes, reduced SOX9 and PRG4 expression, and
accelerated development of OA. These data highlight the important and context-specific role of
the EGFR-Mig-6 signaling pathway in joint homeostasis and point towards potential targeting of
this pathway for OA therapy.
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2.7

Supplemental Figures

Supplementary Figure 1) Construction of the targeting vectors and generation of Mig6over/over mice. Adapted from Kim, T. H. et al. Mig-6 suppresses endometrial cancer associated
with pten deficiency and ERK activation. Cancer Res. 74, 7371–7382 (2014). (A) The
overexpression of Mig-6 is accomplished by placing the transcription of Mig-6 under the control
of a ubiquitously expressed promoter, the chicken b actin-cytomegalovirus hybrid (CAGGS)
promoter. The construction also contained the “Stop Cassette” flanked by LoxP sites (LSL). (B)
PCR strategy. P1 and P2 can amplify a 300 bp fragment from the wild-type allele, whereas P1 and
P3 can amplify a 450 bp fragment from the targeted ROSA26 locus allele. (C) A representative
agarose gel image of PCR genotyping, heterozygous (Het), wild-type (WT) and homozygous
(Homo). (D) PCR primer sequence for wild type and Mig-6LSL allele. (E) RT- PCR primer
sequence for Mig-6over/over. (F) Individual data points presented with mean ± SEM (P<0.05). Data
analyzed by two tailed student t-tests from 11 mice per group.
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Supplementary Figure 1) Construction of the targeting vectors and generation of Mig-6over/over
mice
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Supplementary Figure 2) Bone mineral densities were measured from µCT scan volumes
from control and Mig-6over/over male mice. (A) Mean bone mineral densities were 323.7 mg/cc
(control) and 318.5 mg/cc (Mig-6over/over) at 11 weeks-old. Moreover, (B) At 12 months of age
male Mig-6over/over mice had mean bone mineral density (342.9 mg/cc) and controls male mice
(341.0 mg/cc). (C) At 18 months of age, there were no significance difference between the mean
bone mineral density from control male mice (342.1 mg/cc) and male Mig-6over/over (333.2 mg/cc).
There were not significantly different among 11 weeks-old, 12 and 18 months for bone mineral
density for male control and Mig-6 overexpression mice. Individual data points presented with
mean ± SEM (P<0.05). Data analyzed by two tailed student t-tests from 6-12 mice per group
(age/gender).
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Supplementary Figure 2) Bone mineral densities were measured from µCT scan volumes from
control and Mig-6over/over male mice
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Supplementary Figure 3) Body composition and body mass from growth and aging male
control and Mig-6over/over. Body composition was calculated from control and Mig-6over/over male
mice. At 11 weeks-old (A1/A2), 12 months (B1/B2) and 18 months (C1/C2) neither the average
lean mass percent nor mean body fat were statistically significant between genotypes. Individual
data points presented with mean ± SEM (P<0.05). Data analyzed by two tailed student t-tests from
6-12 mice per group (age/genotyping).
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Supplementary Figure 3) Body composition and body mass from growth and aging male
control and Mig-6over/over
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Supplementary Figure 4) Articular cartilage from 11 weeks-old Mig-6over/over female mice
appeared healthy during skeletal maturity. Representative (n=5/group, toluidine blue) stained
frontal sections of knee joints from 11-week-old control (A) and Mig-6over/over (B). Mig-6
overexpressors mice show similar articular cartilage thickness when compared to controls at 11
weeks-old female mice. The average thickness of the calcified articular cartilage (C) and noncalcified articular cartilage (D) in the lateral femoral condyle (LFC), lateral tibial plateau (LTP),
medial femoral condyle (MFC), medial tibial plateau (MTP) was measured. Individual data points
presented with mean ± SEM. Data analyzed by two-way ANOVA (95% CI) with Bonferroni posthoc test. Scale bar = 100µm.
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Supplementary Figure 4) Articular cartilage from 11 weeks-old Mig-6over/over female mice
appeared healthy during skeletal maturity
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Supplementary Figure 5) 12-month-old Mig-6over/over female mice showed joint damage.
Representative images of Toluidine Blue stained sections of knee joints from 12 month-old female
control (A) and Mig-6over/over (B) mice were evaluated for cartilage damage following the OARSI
histopathological scale on the four quadrants of the knee: LFC = lateral femoral condyle, LTP =
lateral tibial plateau, MFC = medial femoral condyle and MTP = medial tibial plateau. OARSI
based cartilage degeneration scores are higher both in the MFC and MTP of Mig-6 overexpressing
mice, corresponding to the increased damage observed histologically (C). Data analyzed by twoway ANOVA with Bonferroni’s multiple comparisons test. Individual data points presented with
mean ± SEM. All scale bars =100 μm. N = 8 mice/group. Scale bar = 100µm.
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C

Supplementary Figure 5) 12-month-old Mig-6over/over female mice showed joint damage
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Supplementary Figure 6) 18 months-old Mig-6over/over female mice showed increased damage
in the medial tibial plateau. Representative images of Toluidine Blue stained sections of knee
joints from 18 month-old female control (A) and female Mig-6 over (B) mice were evaluated for
cartilage damage following OARSI histopathological scale on the four quadrants of the knee: LFC
= lateral femoral condyle, LTP = lateral tibial plateau, MFC = medial femoral condyle and MTP
= medial tibial plateau. OARSI based cartilage degeneration scores are higher both in the MFC
and MTP of Mig-6 overexpressing mice, corresponding to the increased damage observed
histologically. (C). Data analyzed by two-way ANOVA with Bonferroni's multiple comparisons
test. Individual data points presented with mean ± SEM. All scale bars =100 μm. N = 8 mice/group.
Scale bar = 100µm.
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C

Supplementary Figure 6) 18 months old Mig-6over/over female mice showed joint damage
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Supplementary Figure 7) SOX9 immunostaining shows a decrease in Mig-6 overexpressors
mice at 11 weeks-old male mice control and Mig-6over/over. No primary antibody staining.
Ratio between the total cell number from control and Mig-6over at 11 weeks-old male mice (A).
Ratio between the percentage of Sox9 positive cells from control and Mig-6over at 11 weeks-old
male mice (B). Data analyzed by two-way ANOVA (95% CI) with Bonferroni post-hoc test.
Individual data points presented with mean ± SEM; N= 5 mice/genotyping. LFC = lateral femoral
condyle, LTP = lateral tibial plateau, MFC = medial femoral condyle and MTP = medial tibial
plateau. Scale bar = 100µm.
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Supplementary Figure 7) SOX9 immunostaining shows a decrease in Mig-6 overexpressors
mice at 11 weeks-old male mice control and Mig-6over/over.
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3.1

Abstract

Background: Mitogen-inducible gene 6 (Mig-6) is a tumour suppressor gene that is also
associated with the development of osteoarthritis (OA)-like disorder. Recent evidence from our
lab and others showed that cartilage-specific Mig-6 knockout (KO) mice develop chondro-osseous
nodules, along with increased articular cartilage thickness and enhanced EGFR signaling in the
articular cartilage. Here, we evaluate the phenotype of mice with skeletal-specific overexpression
of Mig-6.
Methods: Synovial joint tissues of the knee were assessed in 12 and 36 weeks-old skeletonspecific Mig-6 overexpressing (Mig-6over/over) and control animals using histological stains,
immunohistochemistry,

semi-quantitative

OARSI

scoring,

and

microCT

for

skeletal

morphometry. Measurement of articular cartilage and subchondral bone thickness were also
performed using histomorphometry.
Results: Our results show only subtle developmental effects of Mig-6 overexpression. However,
male Mig-6over/over mice show accelerated cartilage degeneration at 36 weeks of age, in both medial
and lateral compartments of the knee. Immunohistochemistry for SOX9 and PRG4 showed
decreased staining in Mig-6over/over mice relative to controls, providing potential molecular
mechanisms for the observed effects.
Conclusion: Overexpression of Mig-6 in articular cartilage causes no major developmental
phenotype but results in accelerated development of OA during aging. These data demonstrate that
precise regulation of the Mig-6/EGFR pathway is critical for joint homeostasis.
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3.2

Introduction

Osteoarthritis (OA) is a failure of joint homeostasis and results in the whole-joint tissue
degeneration (1). In fact, OA is a multifactorial disease affecting 630 million individuals
worldwide, and the economic impact of OA treatment is estimated at 190 billion dollars in direct
and indirect health care costs in North America annually (2,3). OA patients experience limits in
daily activities and often suffer from co-morbidities including mental health disorders (4).
Treatment for pain and inflammation (analgesics, non-steroidal anti-inflammatory drugs
(NSAIDS) and targeted physiotherapy (5) are commonly used to address patients’ symptoms, but
no effective pharmacological therapy is currently available to delay disease progression. Future
directions for effective OA management rely on better understanding of joint physiology and
pathophysiological mechanism to develop disease-modifying therapies for OA patients.
Risk factors including aging, genetics, obesity, and trauma contribute to the dysfunction of joint
structures in OA. During the early stages of OA, alteration in chondrocyte physiology including
cluster formation and changes in the composition of extracellular matrix (ECM) lead to altered
cartilage function (6–8). Gradual degeneration of the articular cartilage, subchondral bone
sclerosis, osteophyte development, and synovial inflammation/hyperplasia all contribute to joint
degeneration in OA (9–11). Expression of matrix metalloproteinases (MMPs) (i.e., MMP-1 and
MMP-13) and aggrecanases (disintegrin and metalloproteinase with a thrombospondin type 1
motif (ADAMTS) (i.e., ADAMTS 1,4,5) is up-regulated in response to inflammatory factors and
other signals (12–14). Importantly, the tissues of the whole joint work together to maintain joint
homeostasis. Therefore, failure in one joint structure might lead to failure of the whole organ, such
as the knee joint (15).
Over the past two decades, epidermal growth factor receptor (EGFR) signaling has been studied
in several stages of cartilage development and homeostasis. These studies demonstrate both
degenerative and protective roles of this pathway (16), with potential therapeutic implications for
OA (17–26). EGFR signaling modulates many canonical signaling pathways including MEK/ERK
that have been implicated in cellular proliferation and growth in cartilage and bone, as well as Jun
N-terminal kinases (JNKs), PLC-PKC signaling and others (24,27,28). Mitogen inducible gene 6
(Mig-6) is well-known as a negative regulator for EGFR signaling (29). Two different mouse
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strains with global deletion of Mig-6 demonstrated bone erosion and spontaneous development of
OA-like phenotypes (30,31). Cartilage-specific Mig-6 KO mice display normal early bone
development, but show anabolic buildup of articular cartilage, and formation of chondro-osseous
nodules at 12 and 36 weeks of age (32) . Another study using limb mesenchyme-specific deletion
of Mig-6 in mice (using the Prx1-cre driver line) demonstrated similar phenotypes as those
observed in cartilage-specific knockout mice (33). Our laboratory has shown that cartilage-specific
Mig-6 overexpression in mice results in no major developmental abnormalities in articular
cartilage, however, during aging (12 and 18 months) Mig-6over/over mice show accelerated cartilage
degeneration (34). To evaluate the contribution of Mig-6 in multiple joint tissues to joint
homeostasis and OA pathogenesis, we used Prx1 promoter-driven Cre recombinase to selectively
overexpress Mig-6 in all mesenchymal limb tissues in mice.

3.3

Methods

3.3.1

Animals

All animals and procedures were approved by the Council for Animal Care (CCAC) at Western
University-Canada (Animal use permit:2015-031). Mig-6 overexpression animals with the
overexpression targeted to the Rosa26 locus (35) were backcrossed for 10 generations into a
C57Bl/6 background. In these mice, transcription of Mig-6 is under the control of a ubiquitously
expressed chicken beta actin-cytomegalovirus hybrid (CAGGS) promoter, but blocked by a “Stop
Cassette” flanked by LoxP sites (LSL) (35). Mig-6 overexpression mice were bred to mice
carrying the Cre recombinase gene under the control of the Prx1-Cre transgene (36) to induce
recombination and removal of the Stop Cassette specifically in early limb bud mesenchyme.
Animals with overexpression of Mig-6 from both alleles are termed Mig-6
over/over

over/over

(Mig-6

Prx1-Cre+/-), while control mice are identical but without the Cre gene (denoted “control”

for simplicity). Mice were group housed (2 or 4 mice per cage of littermate matched control and
overexpression animals), on a standard 12 hour light/dark cycle, and with free access to mouse
chow and water. Genotyping and assessment of genomic recombination was performed on DNA
samples from ear tissue from mice surviving to at least 21 days of age. Standard polymerase chain
reaction (PCR) was performed using primer set P1 and P2 can amplify a 300 bp fragment from the
wild-type allele, whereas P1 and P3 can amplify a 450 bp fragment from the targeted ROSA26
locus allele (35).
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3.3.2

Histologic Assessment

The knee joints of mice were dissected and fixed in 4% paraformaldehyde in phosphate buffered
saline (PBS, pH 7.0) for 24 hours at room temperature. The intact joints were then decalcified in
5% ethylenediaminetetraacetic acid (EDTA) in phosphate buffered saline (PBS), pH 7.0 for 10 –
12 days at room temperature. All joints were processed and embedded in paraffin in sagittal or
frontal orientation, with serial sections taken at a thickness of 5 μm. Sections were stained with
Toluidine Blue (0.04% toluidine blue in 0.2M acetate buffer, pH 4.0, for 10 minutes) for
glycosaminoglycan content and general evaluation of articular cartilage.
Immunohistochemistry was performed on frontal sections of paraffin embedded knee joints as
previously described (32,37). Primary antibodies against SOX9 (R&D Systems, AF3075),
MMP13 (Protein Tech, Chicago, IL, USA, 18165-1-AP), and lubricin (Abcam, ab28484) were
used and slides without primary antibody were used as control. Sections were incubated with
primary antibody overnight at 4°C. After washing, sections were incubated with horseradish
peroxidase (HRP)-conjugated donkey anti-goat or goat anti-rabbit secondary antibody (R&D
system and Santa Cruz), before incubation with diaminobenzidine substrate as a chromogen
(Dako, Canada). Finally, sections were counterstained with 0.5% methyl green (Sigma) and
dehydrated in graded series of 70-100% ethanol in water, followed by 100% xylene, and mounted
using xylene-based mounting media. All images were taken using a Leica DM1000 microscope
with attached Leica DFC295 digital camera.

3.3.3

Histologic evaluation of articular cartilage and histopathology scoring

Articular cartilage thickness was determined from toluidine blue-stained frontal sections of knee
joints by a blinded observer with regard to the tissue source. ImageJ Software (v.1.51) (38) was
used to measure the cartilage thickness separately for the non-calcified articular cartilage
(measured from the superficial tangential zone to the tidemark) and the calcified articular cartilage
(measured from the subchondral bone to the tidemark) across three evenly spaced points from all
four quadrants of the joint (medial/lateral tibia and femur), in 4 sections spanning at least 500 μm.
For OARSI scoring, Toluidine blue-stained sections were evaluated by one to two blinded
observers (MB, MAP) on the four quadrants of the knee: lateral femoral condyle (LFC), lateral
tibial plateau (LTP), medial femoral condyle (MFC), and medial tibial plateau (MTP), according
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to the Osteoarthritis Research Society International (OARSI) histopathologic scale (39).
Subchondral bone area from the tibial plateau was traced by one observer (MB) using the
Osteomeasure analysis software (OsteoMetrics, Decatur, GA, USA) for histomorphometry
measurements using three sections spanning at least 500 µm from each animal.

3.3.4

Visualization of collagen fiber content

In order to analyze the collagen fibril content and network, Picrosirius Red Staining (0.1% Sirius
red in saturated picric acid solution for 60 minutes, with 0.5% acetic acid washes) was performed
(32). Stains were imaged under polarized light microscopy to visualize the organization and size
of collagen fibrils. Light intensity and tissue angle (45°) relative to polarizing filter (Leica no.
11505087) and analyzer (Leica no. 11555045) were kept identical between samples as per (32)

3.3.5

Micro-Computerized Tomography (μCT)

Mice were euthanized and imaged using General Electric (GE) SpeCZT microCT machine (40) at
a resolution of 50μm/voxel or 100μm/voxel in 12 and 36 week-old control and Mig-6 over/over male
and female mice. GE Healthcare MicroView software (v2.2) was used to generate 2D maximum
intensity projection and 3D isosurface images to evaluate skeletal morphology (32,41). MicroView
was used to create a line measurement tool in order to calculate the bone lengths; femurs lengths
were calculated from the proximal point of the greater trochanter to the base of the lateral femoral
condyle. Tibiae lengths were measured from the midpoint medial plateau to the medial malleolus.
Humerus lengths were measured from the midpoint of the greater tubercle to the center of the
olecranon fossa.

3.3.6

Statistical Analysis

All statistical analyses were performed using GraphPad Prism (v6.0). Differences between two
groups were evaluated using Student's t-test, and Two-Way ANOVA was used to compare four
groups followed by a Bonferroni multiple comparisons test. All n values represent the number of
mice used in each group/genotyping.
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3.4
3.4.1

Results
Overexpression of Mig-6 has minor effects on body weight during
development

Mice with alleles for conditional overexpression of Mig-6 (35) were bred to mice expressing Cre
recombinase under control of the Prx1 promoter, which is active in the mesenchyme of developing
limb buds. Homozygote mice overexpressing Mig-6 in mesenchymal limb tissue from both Rosa26
alleles are referred to as Mig-6 over/over from here on. Control mice do not express Cre recombinase.
Overexpressing mice were obtained at the expected Mendelian ratios (data not shown). Animal
weights were significantly lower at 7, 12, and 13 weeks after birth in male mutant mice compared
to control mice (Fig. 3.1A), while female Mig-6over/over mice had similar weights as control mice
(Fig. 3.1B). However, at 36 weeks of age mice there were no differences in weights of neither
male nor female mutant mice compared to the control group (Fig. 3.1C, D).
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Figure 3.1 Total body weight of male and female control and Mig-6over/over mice. Total body weight
of 12-week-old male (A) and female (B) mice. Total body weights of 36-week-old male (C) and
female (D) Mig-6over/over mice and controls did not show any statistically significant differences.
Individual data points are presented with mean ± SEM (P<0.05). Data were analyzed by two tailed
student t-tests from 8-10 mice per group (age/genotyping).

128

A

B

C

D

Figure 3.1 Total body weight of male and female control and Mig-6over/over mice
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3.4.2

Mig-6 overexpressing mice show no differences in bone length

Micro computed tomography (microCT) was used to investigate skeletal morphology and bone
length. Whole body microCT scans of Mig-6 over/over male mice and their controls were taken postmortem at 12 and 36 weeks of age to generate 3D isosurface reconstructions of 50μm/voxel μCT
scans, in order to measure long bones lengths (femurs, humeri, and tibiae) in GE MicroView v2.2
software. Mutant male mice at 12 and 36 weeks did not show any difference in bone length
compared to controls (Fig. 3.2A-B). Moreover, no differences in gross skeletal morphology were
detected (Fig. 3.2C).
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Figure 3.2 Mig-6 overexpression does not affect bone length. The lengths of right femora, tibiae
and humeri were measured on microCT scans of mice at 12 (A) and 36 (B) weeks of age using GE
MicroView software. There were no statistically significant differences in any bones at either age.
Individual data points are presented with mean ± SEM (P<0.05). Data were analyzed by two tailed
student t-tests from 8 mice per group (age/gender). (C) shows a representative 3D isosurface
reconstruction of a 100μm/voxel µCT scan.
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Figure 3.2 Mig-6 overexpression does not affect bone length
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3.4.3

Specific overexpression of Mig-6 in limbs display healthy articular
cartilage at skeletal mature

Histological analysis of knee sections was performed on 12-week-old mutant and control male
mice using toluidine blue stained paraffin frontal knee sections (Fig. 3.3A-B). No major
differences in tissue architecture were seen between genotypes. However, the thickness of the
calcified articular cartilage in the medial femoral condyle (MFC) and medial tibial plateau (MTP)
of male Mig-6

over/over

mice was statistically significantly lower than in controls. Uncalcified

cartilage did not show any differences between genotypes.
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Figure 3.3 12-week-old Mig-6over/over male mice show healthy articular cartilage.
Representative (n=5) toluidine blue-stained frontal sections of knee joints from 12-week-old
control (A, B) and Mig-6over/over (C, D) mice showed no apparent damage. Mig-6 overexpressing
mice did show statistically significant differences in thickness of the calcified articular cartilage
on the medial femoral condyle (MFC) and medial tibial plateau (MTP) (E) when compared to
controls. However, no statistically significant differences were seen in the non-calcified articular
cartilage (F). The lateral femoral condyle (LFC) and lateral tibial plateau (LTP) did not show any
significant differences. Individual data points are presented with mean ± SEM. Data were analyzed
by two-way ANOVA (95% CI) with Bonferroni post-hoc test. Scale bar = 100µm.
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Figure 3.3 12-week-old Mig-6over/over male mice show healthy articular cartilage
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3.4.4

Mig-6 overexpressing male mice display articular cartilage damage at 36
weeks of age

We evaluated the knee joints of 36 weeks-old control and Mig-6 over/over male mice using toluidine
blue staining and OARSI grading method (39). At this age, control mice exhibited little to no
damage of articular cartilage (Fig. 3.4A). Conversely, three of seven Mig-6 over/over mice exhibited
cartilage damage and erosion with significantly elevated scores in the medial compartment of the
knee. Moreover, all seven Mig-6 over/over mice had OA in the lateral compartment of the knee (Fig.
3.4B), with fibrillation and fissure formation. Furthermore, two of six Mig-6 over/over female mice
showed mild cartilage degeneration of the medial compartment (Fig. 3.5B), in contrast to the
control group where no cartilage damage was observed (Fig. 3.5A).

136

Figure 3.4 Cartilage damage in knee joints of 36-week-old male Mig-6 overexpressing mice.
Toluidine blue staining demonstrated healthy knee joints and articular cartilage in all 36-week-old
male control mice (A), while many Mig-6-overexpressing mice showed clear damage to the
articular surface (B). OARSI histopathology scoring demonstrated that cartilage degeneration
scores significantly increased in the MFC, MTP, LFC and LTP of Mig-6 overexpressing mice. (C)
Data were analyzed by two-way ANOVA with Bonferroni's multiple comparisons test. Individual
data points are presented with mean ± SEM. All scale bars =100 μm. N = 7 mice/group.
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Figure 3.4 Cartilage damage in knee joints of 36 week-old male Mig-6 overexpressing mice
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Figure 3.5 Minor damage in articular cartilage of 36-week-old female Mig-6 overexpressing
mice. (A) Paraffin sections of knee joints from 36-week-old female control (A) and Mig-6
overexpressing (B) mice demonstrated healthy joints in controls and minor cartilage damage in
some mutant mice, which was confirmed by OARSI histopathology scoring (C). Data were
analyzed by two-way ANOVA with Bonferroni's multiple comparisons test. Individual data points
are presented with mean ± SEM. All scale bars =100 μm. N = 7 mice/group.
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Figure 3.5 Minor damage in articular cartilage of 36-week-old female Mig-6 overexpressing
mice
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3.4.5

Specific overexpression of Mig-6 results in normal bone area

Bone structural alteration is related to knee osteoarthritis as an adaptive response to the loading
distribution across joints (42). Measurement of the subchondral bone area from Mig-6 over/over and
controls male mice at 36 weeks-old across the entire joint did not reveal any significant differences
between genotypes (Fig. 3.6A-B). Specific measurements of the lateral and medial tibia plateau
did not show any significant differences either (data not shown).
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Figure 3.6 No differences in the subchondral bone area upon overexpression of Mig-6. The
subchondral bone area from 12-week-old male control and Mig-6 overexpressing (A) or 36-weekold male control and Mig-6 overexpressing (B) mice are shown. Representative images of the
subchondral area selected using the OsteoMeasure bone histomorphometry system are shown in
(C). Individual data points are presented with mean ± SEM. Data were analyzed by one observer
(MB). All scale bars =100 μm. N = 6-7 mice/group.

142

Figure 3.6 No differences in the subchondral bone area upon overexpression of Mig-6.
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3.4.6

Mig-6 overexpressing mice display altered collagen fiber organization in
articular cartilage

Frontal sections from 36 weeks-old male mice were stained with Picrosirius red to visualize the
collagen network under polarized light microscope. In the control male mice, the collagen fibers
in the articular cartilage exhibit greenish/yellow birefringence in the superficial and transitional
zones, resulting from thin collagen fibers in these regions. In the deep and calcified cartilage, and
in bone, red birefringent fibers are visualized, indicating larger fiber diameter in these regions. The
articular cartilage of Mig-6 over/over showed fewer green collagen fibers in the medial compartment
of the knee, indicating a loss of normal collagen fibers (Fig. 3.7A-B).
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Figure 3.7 Picrosirius Red Staining of control and Mig-6 overexpressing mice.
Representative paraffin sections of the medial and lateral compartment in 36-week-old male
control (A) and Mig-6 overexpressing mice (B) were stained with picrosirius red (fibrillar
collagen) and analyzed under polarized light to evaluate the collagen tissue organization and
orientation in the articular cartilage. Cartilage in the medial compartment of Mig-6over/over mice
shows reduced collagen staining. N=5 mice/group; LFC = lateral femoral condyle, LTP = lateral
tibial plateau, MFC = medial femoral condyle and MTP = medial tibial plateau. Scale bar = 100µm.
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Figure 3.7 Picrosirius Red Staining of control and Mig-6 overexpressing mice
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3.4.7

Overexpression of Mig-6 decreases Sox9 expression

Studies have shown that expression of the transcription factor SRY (sex determining region Y)box 9 [SOX9] was increased in articular cartilage upon both Prx1-Cre 1(43) and Col2-Cre-driven
(32) deletion of Mig-6. SOX9 is an essential regulator of chondrogenesis and the maintenance of
a chondrocyte-like phenotype (44). Frontal sections of paraffin embedded knees from 12- and 36week-old male mice were used for SOX9 immunostaining. In 12-week-old control mice, nuclear
SOX9 was abundantly present in the articular cartilage of the knee joints in all four quadrants. In
contrast, Mig-6 over/over mice appear to have fewer cells staining positive in both lateral and medial
compartments (Fig. 3.8A, B). 36-week-old Mig-6 over/over mice showed a further reduction in SOX9
immunostaining in the lateral quadrant, while the loss of cartilage in the medial compartment led
to an absence of SOX9 staining (Fig. 3.9A, B). For both ages, negative controls did not show
staining in chondrocytes (data not shown).
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Figure 3.8 Lower numbers of SOX9-positive cells in 12-week-old male Mig-6 overexpressing
mice. Representative SOX9 immunostaining in knee joints of 12-week-old male control (A) or
Mig-6 overexpressing (B) mice (n=5 mice/group). Ratio between the total cell number from
control and Mig-6 over/over mice in 12-week-old male mice (C). Ratio between the percentage of
Sox9 positive cells from control and Mig-6 over/over at 12-week-old male mice (D). Data analyzed
by two-way ANOVA (95% CI) with Bonferroni post-hoc test. Individual data points presented
with mean ± SEM; N= 5 mice/genotyping. LFC = lateral femoral condyle, LTP = lateral tibial
plateau, MFC = medial femoral condyle and MTP = medial tibial plateau. Scale bar = 100µm.
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Figure 3.8 Lower numbers of SOX9-positive cells in 12-week old male Mig-6 overexpressing
mice.
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Figure 3.9 Lower numbers of SOX9-positive cells in 36-week old male Mig-6 overexpressing
mice.

Representative SOX9 immunostaining in knee joints of 36-week-old male control (A) or

Mig-6 overexpressing (B) mice (n=5 mice/group). Overexpressing mice showed reduced numbers
of positive cells in the medial and lateral compartments. LFC = lateral femoral condyle, LTP =
lateral tibial plateau, MFC = medial femoral condyle and MTP = medial tibial plateau. Scale bar
= 100µm.
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Figure 3.9 Lower numbers of SOX9-positive cells in 36-week old male Mig-6 overexpressing
mice
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3.4.8

Lubricin/PGR4 is decreased upon Mig-6 overexpression

Lubricin/proteoglycan 4 plays an important role as joint boundary lubricant and is produced by
synoviocytes as well as superficial zone chondrocytes (45,46). In 12-week-old Mig-6 over/over mice,
lubricin was observed in superficial zone (SZ) and middle zone (MZ) chondrocytes, in a similar
pattern as control mice, although intensity appeared reduced in Mig-6 over/over mice (Fig. 3.10 AC). 36-week-old control male mice show lubricin immunostaining in the SZ and MZ, however,
less lubricin immunostaining is present in the SZ of the medial side of Mig-6 over/over mice. Negative
controls did not show staining in chondrocytes or articular cartilage at either age (Fig. 3.10 A-C).
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Figure 3.10 Lubricin immunostaining is slightly decreased in the articular cartilage of Mig6 overexpressing mice at 12 weeks of age. Immunostaining of sections of the knee joint indicate
the presence of Lubricin (PRG4) in the superficial zone chondrocytes of 12-week-old male control
mice (A), with apparently reduced staining in Mig-6 overexpressing mice (B). Ratio between
the total cell number from control and Mig-6 over/over at 12-week-old male mice (C). Ratio between
the percentage of Lubricin (PRG4) positive cells from control and Mig-6 over/over mice at 12 weeks
of age (D). Data analyzed by two-way ANOVA (95% CI) with Bonferroni post-hoc test. Individual
data points presented with mean ± SEM; N= 5 mice/genotyping. LFC = lateral femoral condyle,
LTP = lateral tibial plateau, MFC = medial femoral condyle and MTP = medial tibial plateau.
Scale bar = 100µm.
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Figure 3.10 Lubricin immunostaining is decreased in the articular cartilage of Mig-6
overexpressing mice at 12 weeks of age
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3.4.9

MMP13 immunostaining is increased in Mig-6-overexpressing compared
to control mice

Previous studies have shown that matrix metalloproteinase (MMP) 13 is the main collagenase
associated with type II collagen destruction in OA. Frontal sections of knees from 36-week-old
control and Mig-6 over/over male mice were used for MMP13 immunohistochemistry. While some
staining was seen in control mice, intensity of staining was increased in areas of damage on the
medial side of Mig-6

over/over

mice. Negative controls did not show staining in cartilage or

subchondral bone (Fig. 3.11 A, B, and C).
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Figure 3.11 36-week-old Mig-6 overexpressing mice show increased MMP13 staining in
cartilage. Representative immunohistochemistry of matrix metalloproteinase 13 (MMP13) in 36week-old control (A) and Mig-6 overexpressing (B) mice show increased staining in the degrading
cartilage of overexpressors. No primary antibody control is shown in (C). N=5 mice/genotyping.
LFC = lateral femoral condyle, LTP = lateral tibial plateau, MFC = medial femoral condyle and
MTP = medial tibial plateau. Scale bar = 100µm.
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Figure 3.11 36-week-old Mig-6 overexpressing mice show increased MMP13 staining in
cartilage
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3.5

Discussion

Mig-6 has been studied in a variety of human diseases, including cancer and more recently OA
progression(16,31–33,47). Many studies, including from our lab, also identified TGFα /EGFR
signaling as a regulator of OA progression and cartilage homeostasis (21,24,48). Interestingly,
cartilage-specific (Col2-Cre) deletion of Mig-6 (Mig-6 KO) (32) results in increased proliferation
of chondrocytes and a thicker layer of cartilage while skeletal-specific (Prx1-Cre) deletion of Mig6 results in transient anabolic buildup of cartilage followed by catabolic events such as cartilage
degeneration at 16 weeks of age (33). In fact, global deletion of Mig-6 in mice results in a complex
set of phenotypes, including joint damage at relatively early time-points in a surgical mouse model
(31,49,50). Previous research demonstrates that Mig-6 acts as a negative feedback inhibitor of
EGFR signaling (51). Thus, Mig-6 has been suggested as a potential tumor suppressor, as a
suppressor of EGFR signaling in human carcinomas (35,52–55). Recent work has revealed that
overexpression of Mig-6 acts as a negative regulator of EGFR-ERK signalling in mouse uterus
(35). In our study, we set out to evaluate the role of Mig-6 in joint physiology by using skeletalspecific constitutive overexpression of Mig-6. In this study, we show no major effects of Mig-6
overexpression on bone length at the ages of 12 or 36 weeks. While male Mig-6over/over mice did
show slightly reduced body weight up to 12 weeks after birth, these differences were no longer
present at 36 weeks of age.
Our results show that Mig-6over/over (Prx1-Cre) male mice developed cartilage lesions at 36 weeks
of age, where control mice show healthy cartilage. OARSI scores of Mig-6over/over mice reveal
significantly increased cartilage degeneration compared to control group. Surprisingly, it appeared
that cartilage degeneration in Mig-6over/over mice was not accompanied by any obvious changes in
subchondral bone. However, the thickness of the calcified articular cartilage in Mig-6over/over was
significantly decreased at the 12-week time-point, at least in the medial compartment. It is
currently unclear whether and how this is related to the subsequent degeneration of articular
cartilage in these mice.
SOX9 is a transcription factor that is necessary for the formation of mesenchymal condensations
as well as chondrocyte differentiation and proliferation (56,57). Our data suggest a lower number
of SOX9-positive cells at the 12-week time point in mutant mice, preceding cartilage damage. The
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number of SOX9-expressing cells is further reduced in 36-week-old mutant mice, although this is
partially due to the loss of cartilage and chondrocytes. In agreement with these data, mice with
cartilage- or limb mesenchyme-specific deletion of Mig-6 showed increased expression of SOX9
in the articular cartilage (32,33).
Lubricin/PRG4 is necessary for joint lubrication and to maintain healthy cartilage (58,59). Our
results suggest a slight decrease in lubricin staining in 12 weeks-old male Mig-6

over/over

mice,

compared to the control group. We also observed the same trend towards decreased staining in 36
weeks-old male Mig-6 over/over mice. Together, these data suggest that the decreased of SOX9
and lubricin in the articular cartilage could contribute to cartilage degeneration in our mutant mice.
We recently described mice with cartilage-specific (Col2-Cre-driven) overexpression of Mig-6
(34). Despite the differences in recombination patterns conferred by the two different Cre drivers,
overall the phenotypes observed upon Mig-6 overexpression are quite similar.

Both are

characterised by no or only subtle developmental defects, followed by reduced SOX9 and lubricin
expression, followed by cartilage degeneration. One unique feature of the Prx1-driven Mig6overexpression described here is the stronger OA phenotype in the lateral compartment of 36week-old mutant male mice. Future studies will need to investigate the underlying causes.
While Mig-6 had been identified as a negative regulator of EGFR signaling, it also interacts with
a number of other potential candidate proteins that may contribute to the phenotype described here,
such as Cdc42 (60), c-Abl (61), and the hepatocyte growth factor receptor c-Met (62). Therefore,
additional work is necessary to elucidate the potential role of these proteins in the phenotype
presented. In conclusion, in this study using limb mesenchyme-specific Mig-6 overexpression we
show a reduction of SOX9 and PRG4 expression, and accelerated cartilage damage. The data
highlights the importance of more studies on the specific role of Mig-6 signaling in joint
homeostasis and OA development.
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Chapter 4
Cartilage-Specific Overexpression of Mig-6 Accelerates PostTraumatic Osteoarthritis in Mice
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4.1 Abstract
Background: Osteoarthritis (OA) is a chronic degenerative disease characterised by cartilage loss
and changes in the whole joint (e.g. subchondral bone sclerosis, osteophyte formation, synovitis).
Moreover, OA leads to pain, loss of joint function as well as a decrease in quality of life. Currently,
there is no cure for OA. Several studies have shown that molecular derangement is involved in the
disruption of joint homeostasis and imbalance between catabolic and anabolic signals. Mitogeninducible gene 6 (Mig-6) has been identified as a potential regulator of cartilage physiology. Our
lab has demonstrated that cartilage-specific Mig-6 knockout (KO) mice develop osteophyte-like
chondro-osseous nodules in the knee joints and anabolic increase in articular cartilage thickness.
Recently, our previous study showed that cartilage- or limb mesenchyme-specific Mig-6
overexpression in mice results in cartilage degeneration during aging. Here we examine the effects
of cartilage-specific Mig-6 overexpression on post-traumatic OA in the DMM model.
Methods: Cartilage-specific Mig-6 overexpressing (Mig-6over/over) and control mice underwent
destabilization on medial meniscus (DMM) to induce PTOA at 16 weeks of age. Mice were
sacrificed 8 weeks after surgery. Behavioural outcomes were analyzed through Open Field Testing
prior to sacrifice. Joint pathology was examined using histopathological scoring (semi-quantitative
OARSI scoring) using Toluidine Blue staining of paraffin sections of knee joints.
Results: Mice undergoing DMM surgery exhibited behavioral changes (less movement and
vertical activity) between genotypes. Control and Mig-6over/over DMM operated mice show
significant cartilage degeneration compared to sham operated using OARSI scoring of cartilage.
Conclusion: Surgical-induced OA mice with overexpression of Mig-6 in articular cartilage
significantly aggravated the destruction of articular cartilage. However, Mig-6over/over did not
significantly exhibited behaviour changes. These results suggested that Mig-6over/over indicate to
alter disease progression of OA.
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4.2

Introduction

Mitogen-inducible gene 6 (Mig-6) has been implicated in a variety of human diseases such as lung
cancer, including squamous cell carcinoma, non-small cell lung cancer, and osteoarthritis (1–5).
Biochemically, Mig-6 has been identified as a negative regulator of Epidermal Growth Factor
Receptor (EGFR) signaling (6–8), which regulates many aspects of cell physiology, such as
proliferation and differentiation (9,10). Cartilage- or limb mesenchyme-specific Mig-6
overexpression (in Mig-6 over/over mice) results in accelerated cartilage degeneration during aging
(12 and 18 months) (11,12). In contrast, cartilage-specific Mig-6 knockout (KO) mice show
increased articular cartilage thickness but also ectopic chondro-osseous nodules in their knee joints
(13). Limb mesenchyme-specific Mig-6 deletion (using Prx1-cre) drive resulted in similar
transient anabolic phenotype including cartilage thickening that was followed by catabolic effects
such as matrix degradation (14).

However, global deletion of Mig-6 led to early-onset

osteoarthritis (OA) such as formation of bone cysts and degradation of articular cartilage (2).
Therefore, numerous studies have shown that Mig-6 plays an important role in articular cartilage
homeostasis and maintenance.
OA is the most highly prevalent degenerative joint disease in humans (15–17). OA pathogenesis
is a complex process that leads to alteration in the whole joint and its different structures including
articular cartilage, menisci, ligaments, subchondral bone, and synovium (18,19). OA has
multifactorial causes including systemic and local factors such as genetic susceptibility, trauma
(posttraumatic OA/PTOA), female sex, obesity, muscle weakness, all of which can lead to earlyonset OA (20). Currently the treatments options available for OA are pharmacological, nonpharmacological, and alternative medicine, but none of these address the cause of the disease or
slow disease progression (21). Furthermore, surgical OA treatment (e.g. joint replacement) is a last
resort, based on OA stage, patient’s age and comorbidities, and physical examination/activity (22).
In this study, we evaluated the effects of cartilage-specific Mig-6 overexpressing (Mig-6over/over)
on the development of osteoarthritis following surgical destabilization of medical meniscus
(DMM). DMM is a widely accepted and well validated model of posttraumatic OA (23).
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4.3

Methods

4.3.1

Animals

All mice were bred and housed in accordance with Council for Animal Care (CCAC) guidelines
at The University of Western Ontario. Male mice were group housed (2 or 4 mice per cage,
matched control and overexpressing animals), on a standard 12 hour light/dark cycle, and with free
access to mouse chow and water. Mice were separated to double housing post-surgery. To
conditionally overexpress Mig-6 in chondrocytes, Mig-6 overexpression animals were bred with
Col2-Cre mice as described (11,24). Genotyping was performed on DNA samples from ear tissue
of mice at 21 days of age. Standard polymerase chain reaction (PCR) was performed using primer
set P1 and P2 that amplify a 300 bp fragment from the wild-type allele, whereas P1 and P3 can
amplify a 450 bp fragment from the targeted ROSA26 locus allele (24).
Post-traumatic OA was induced at 16 weeks of age by performing DMM surgery on the right hind
limb of male Mig-6 over/over and control littermates mice, as described (23,25). DMM or Sham
surgery was performed by Dr. Supinder K. Bali. 34 mice were used for this surgical trial, 16 control
(9DMM, 7sham) and 18 Mig-6 over/over mice (9 DMM, 9 sham). Isofluorane was used as surgical
anesthetic. Buprenorphine (dose: 1.0mg/ml) was administered subcutaneously as an analgesic, and
ampicillin (dose: 0.1ml) was administered subcutaneously as a prophylactic antibiotic. 1 week
after surgery, running wheels were added to the cages of all experimental animals, and they had
free access for the remainder of the trial. All mice were sacrificed 8 weeks following surgery by
CO2 asphyxiation and operated right limbs were harvested.

4.3.2

Histologic Assessment

Knee joints of mice were harvested 8 weeks following surgeries and fixed in 4% paraformaldehyde
in phosphate buffered saline (PBS, pH 7.0) for 24 hours at room temperature. The intact joints
were then decalcified in 5% ethylenediaminetetraacetic acid (EDTA) in phosphate buffered saline
(PBS), pH 7.0 for 10 – 12 days at room temperature. All joints were processed and embedded in
paraffin in sagittal or frontal orientation, with serial sections taken at a thickness of 5 μm. Sections
were stained with Toluidine Blue (0.04% toluidine blue in 0.2M acetate buffer, pH 4.0, for 10
minutes) for glycosaminoglycan content and general evaluation of articular cartilage. Sections
through the entire joint were scored according to the Osteoarthritis Research Society International
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(OARSI) histopathologic scale (26) by one blinded observer. Scores from 0-6 represent OA
severity, with 0 referring to healthy cartilage and 6 denoting erosion of more than 75% of articular
cartilage. Individual scores are averaged across the four quadrants of the knee: lateral femoral
condyle (LFC), lateral tibial plateau (LTP), medial femoral condyle (MFC), and medial tibial
plateau (MTP) from each animal/group.

4.3.3

Behavioural Testing

Exploratory behaviour and motor activity in mice were assessed using mouse open field activity
monitors (AccuScan Instruments, Omnitech Electronic, Columbus, OH) with a transparent
Plexiglas cage (height = 40cm, width = 20cm, and length = 20cm). Mice were placed in an Open
Field Tester for 30 minutes, prior to sacrifice. Rest, movement, ambulation, and vertical activity
time and incidence were measured and analyzed using the Fusion Software provided by the
manufacturer.

4.3.4

Statistical Analysis

All statistical analyses were performed using GraphPad Prism (v8.0). Behavioural measures were
analyzed by two-way analysis of variance (ANOVA) followed by Turkey’s multiple comparisons
test. OARSI scores were compared using a two-way ANOVA followed by Turkey’s multiple
comparisons test.

4.4
4.4.1

Results
Overexpression of Mig-6 in cartilage increases severity of DMM-induced
osteoarthritis

Male Mig-6 over/over and control mice received either SHAM or DMM surgery. At 8 weeks postsurgery, mice were euthanized, and their joints were harvested for histopathologic analyses to
evaluate the effect of Mig-6 overexpression on the progression of OA. Serial frontal sections per
mice were assessed semi-quantitatively by 1 blinded observer using the OARSI recommendation
(26). SHAM-operated mice displayed healthy joints, as expected, with only very minor damage in
a few cases. Histologically, varying degrees of cartilage damage in the medial compartment was
seen in all 9 control and all 9 Mig-6 over/over DMM-operated animals. Four of nine control mice
showed mild cartilage degeneration, with focal, full thickness cartilage lesions spanning limited
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areas through the joint. One of nine control mice showed extensive cartilage erosion, spanning 50100% of the articular surface across the entire medial compartment. In Mig-6 over/over mice, five of
nine DMM operated mice showed full thickness cartilage erosion spanning 75% to 50% of the
articular surface across the entire width of the joint. However, four of nine DMM operated mice
showed milder phenotypes, with cartilage erosion spanning 50% to 25% of the articular surface
across the entire medial compartment (Fig 4.1A-B). Semi-quantitative OARSI scoring of the
medial compartment confirmed that Mig-6 over/over mice had significantly higher damage after
DMM surgery than control mice after the same surgery (Fig. 4.2A-B). As expected, lateral
compartments showed very little damage and no significant differences between all groups (Fig.
4.3A-B and Fig. 4.4A-B).
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Figure 4.1 Overexpression of Mig-6 in cartilage increases severity of surgically induced
osteoarthritis. Male Mig-6 over/over and control mice received either SHAM or DMM surgery. 8
weeks after surgery, animals were sacrificed, and OA was assessed by Toluidine Blue staining on
serial frontal sections. SHAM operated control or mutant mice show healthy cartilage, subchondral
bone and menisci (A). Control mice showed moderate cartilage damage after DMM surgery (B).
However, Mig-6 over/over mice showed cartilage erosion and full thickness defects after DMM
surgery. All scale bars =100 μm. N=7-9 per group.
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Figure 4.1 Overexpression of Mig-6 in cartilage increases severity of surgically induced
osteoarthritis
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Figure 4.2 Semi-quantitative assessment of knee joint histopathology after surgical induction
of PTOA. Structural progression of OA was semi-quantitatively assessed via OARSI scoring for
cartilage degeneration. Control SHAM operated mice show articular cartilage with regular
proteoglycan staining (A). Mig-6 over/over DMM operated mice had significantly more cartilage
damage in either quadrant of the medial side versus control DMM operated animals. N=7-9 per
group, data shown are mean ± SEM, p<0.05.
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Figure 4.2 Semi-quantitative assessment of knee joint histopathology after surgical induction of
PTOA
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Figure 4.3 Overexpression of Mig-6 in cartilage show healthy articular cartilage on lateral
compartment of the knee. SHAM control or mutant mice show healthy cartilage, subchondral
bone and menisci (A). DMM control and mutant mice reveal little proteoglycan loss or articular
cartilage damage in the lateral femoral condyle and lateral tibial plateau 8 weeks post-surgery (B).
All scale bars =100 μm. N=7-9 per group.
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Figure 4.3 Overexpression of Mig-6 in cartilage show healthy articular cartilage on lateral
compartment of the knee
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Figure 4.4 OARSI scoring does not indicate differences in lateral compartments of the knee
after SHAM or DMM surgery. OARSI scores of the Lateral Femoral Condyle and the Lateral
Tibial Plateau indicate minimal damage to the articular surfaces across genotypes and surgical
conditions of the lateral knee. N=7-9 per group, data shown are mean ± SEM, p≤0.05.
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Figure 4.4 OARSI scoring does not indicate differences in lateral compartments of the knee after
SHAM or DMM surgery
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4.4.2

Mig-6 overexpressing male mice show minor alterations in behaviour postsurgery

To evaluate changes in behaviour that could be indicative of pain, mice were examined through
Open Field Testing to measure changes in spontaneous locomotor activity. 8 weeks post-surgery,
most parameters examined (including distance travelled, horizontal activity, rest time etc.) did not
show any statistically significant differences in response to either DMM surgery or genotype.
However, vertical activity count was reduced in Mig-6 over/over mice in both SHAM and DMM
groups (Fig. 4.5).
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Figure 4.5 Mig-6 overexpressing mice show reduced vertical activity. Open Field Testing 8
weeks after DMM surgery demonstrates no changes in most spontaneous locomotor activities.
However, Mig-6 overexpression reduces vertical activity count compared to control mice,
independent of the type of surgery. N=7-9 per group, data shown are mean ± 95%CI; p≤0.05.
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Figure 4.5 Mig-6 overexpressing mice show reduced vertical activity.
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4.5

Discussion

Recently, we have shown that cartilage-specific overexpression of the gene encoding MitogenInducible gene 6 (Mig-6) develop accelerated cartilage degeneration during aging (11). A similar
phenotype was seen when Mig-6 was overexpressed using the limb mesenchyme-specific Prx1
promoter (12). However, there is increasing evidence that OA is a heterogeneous disease, with
multiple phenotypes potentially progressing through different processes (27–29). Therefore,
results from our aging studies cannot be extrapolated to other forms of OA. Here, we analyze the
role of Mig-6 in a mouse model of post-traumatic OA. Using mice with cartilage-specific
constitutive overexpression of Mig-6, initially characterised by our lab (11), in comparison to
control mice, we utilized DMM surgery to induce knee OA. Histological analysis and OARSI
scores revealed that Mig-6 overexpression resulted in an increased catabolic response to DMM
surgery at 8 weeks-post surgery. Damage was largely limited to the medial joint compartment, as
is usually seen in the DMM model. Importantly, SHAM-operated mice showed little to no damage
(with a few exceptions in both genotypes). Thus, Mig-6 overexpression does not induce cartilage
damage on its own at the age of 6 months (the age of sacrifice for these mice), but accelerates
development of post-traumatic damage. The combination of genetic manipulation and surgeryinduced mechanical stress appears to accelerate cartilage degeneration, in line with the reported
upregulation of endogenous Mig-6 expression after cartilage impact in a dog model (30–32).
In our previous study we had demonstrated accelerated OA in the same cartilage-specific Mig-6
overexpressing mice at 12 months of age (11). In conjunction with the phenotypes of our SHAMoperated mice described here, these data indicate that primary OA pathogenesis begins between 6
and 12 months of age in these mice. Future studies will need to address the molecular pathways
involved; for example, our results (11) suggest that down-regulation of Sox9 expression precedes
cartilage degeneration. This is, to our knowledge, the first study to analyze exploratory motor
behaviour using open field testing in mice with induced post-traumatic knee OA. Our findings
indicate that most parameters were not changed by either DMM surgery or Mig-6 overexpression.
However, Mig-6 overexpression decreased vertical activity (rearing). Rearing had been shown to
be affected by DMM surgery using the LABORAS behavioral platform (33), which appears logical
since it involves increased loading on the hind limbs, including the DMM-operated knee.
However, in our study, DMM surgery itself did not affect vertical activity in either genotype.
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Instead, we found Mig-6 overexpression to decrease this activity both after SHAM and after DMM
surgeries. The underlying cause is unclear at this point. It should be noted that changes in these
open field tests are not necessarily related to OA pain, but could be caused by effects in other
tissues (e.g. muscle weakness), or by anxiety or depression. Given that our animals are cartilagespecific transgenic mice, and that there is no apparent histological defect in SHAM-operated
animals (that demonstrate reduced vertical activity), such effects appear less likely, but cannot be
ruled out completely. Direct analyses of pain, for example through von Frey filaments or hot plate
assays, could provide a more direct readout of whether increased histological OA damage in Mig6-overexpressing mice correlates with increased pain. In addition, later time points after surgery
could result in clearer effects on pain and activity. A limitation of this study is the focus on male
mice only. This was done since the DMM model progresses more rapid in males (23), and since
Mig-6 overexpression had more severe effects during aging in males (11). Nevertheless, future
studies should include female Mig-6-overexpressing mice. Additional future studies should
examine more time points (e.g. 4, 12, and possibly 16 weeks after surgery) as well as underlying
molecular changes.
Altogether, our studies indicate that Mig-6 overexpression not only accelerates the development
of primary OA during aging, but may also worsen posttraumatic OA pathogenesis in the DMM
model. Since Mig-6 primarily acts through down-regulation of EGFR activity, these data indicate
a requirement for EGFR signaling in protecting from DMM-induced damage, in line with recent
studies (34–36). This is in contrast to the protective effects observed upon genetic deletion of the
gene for TGFα, an EGFR ligand, in the DMM model (37) and to the effects of a small molecule
EGFR inhibitor in a rat model of PTOA (38). However, the context-specific roles of this pathway
in OA have been recognized and discussed recently (39). This study provides further insight into
the complex role of this pathway in OA.

185

4.6

Acknowledgements

We would like to thank Dr. Michael Pest for his assistance in the blinded scoring of joints. M.B.
was supported by a fellowship from CNPq/Brazil. Work in the lab of F.B. is supported by a grant
from the Canadian Institutes of Health Research (Grant #332438). F.B. holds the Canada Research
Chair in Musculoskeletal Research.

186

4.7

References

1.

Tseng, R.-C. et al. Genomewide loss of heterozygosity and its clinical associations in non
small cell lung cancer. Int. J. Cancer 117, 241–247 (2005).

2.

Zhang, Y.-W. et al. Targeted disruption of Mig-6 in the mouse genome leads to early onset
degenerative joint disease. Proc. Natl. Acad. Sci. U. S. A. 102, 11740–5 (2005).

3.

Mateescu, R. G., Todhunter, R. J., Lust, G. & Burton-Wurster, N. Increased MIG-6 mRNA
transcripts in osteoarthritic cartilage. Biochem. Biophys. Res. Commun. 332, 482–6 (2005).

4.

Jin, N., Gilbert, J. L., Broaddus, R. R., DeMayo, F. J. & Jeong, J.-W. Generation of a Mig6 conditional null allele. genesis 45, 716–721 (2007).

5.

Velasquillo, C. et al. Expression of MIG-6, WNT-9A, and WNT-7B during osteoarthritis.
Ann. N. Y. Acad. Sci. 1117, 175–80 (2007).

6.

Hackel, P. O., Gishizky, M. & Ullrich, A. Mig-6 Is a Negative Regulator of the Epidermal
Growth Factor Receptor Signal. Biol. Chem. 382, (2001).

7.

Ferby, I. et al. Mig6 is a negative regulator of EGF receptor–mediated skin morphogenesis
and tumor formation. Nat. Med. 12, 568–573 (2006).

8.

Zhang, Y.-W. & Vande Woude, G. F. in Futur. Asp. Tumor Suppressor Gene (InTech,
2013). doi:10.5772/54393

9.

Anastasi, S., Castellani, L., Alemà, S. & Segatto, O. A pervasive role for MIG6 in
restraining cell proliferation. Cell Death Differ. 21, 345–347 (2013).

10.

Zhang, X., Gureasko, J., Shen, K., Cole, P. A. & Kuriyan, J. An Allosteric Mechanism for
Activation of the Kinase Domain of Epidermal Growth Factor Receptor. Cell 125, 1137–
1149 (2006).

11.

Bellini, M., Pest, M. A., Miranda-Rodrigues, M., Jeong, J. & Beier, F. Overexpression of
mig-6 in cartilage induces an osteoarthritis-like phenotype in mice. bioRxiv 764142 (2019).
doi:10.1101/764142

12.

Bellini, M. R., Pest, M. A., Jeong, J.-W. & Beier, F. Overexpression Of Mig-6 In Limb
Mesenchyme Leads To Accelerated Osteoarthritis In Mice. bioRxiv 871350 (2019).
doi:10.1101/871350

13.

Pest, M. A., Russell, B. A., Zhang, Y.-W., Jeong, J.-W. & Beier, F. Disturbed cartilage and
joint homeostasis resulting from a loss of mitogen-inducible gene 6 in a mouse model of
joint dysfunction. Arthritis Rheumatol. (Hoboken, N.J.) 66, 2816–27 (2014).

14.

Shepard, J. B., Jeong, J.-W., Maihle, N. J., O’Brien, S. & Dealy, C. N. Transient anabolic
effects accompany epidermal growth factor receptor signal activation in articular cartilage

187
in vivo. Arthritis Res. Ther. 15, R60 (2013).
15.

Centers for Disease Control and Prevention (CDC). Prevalence of doctor-diagnosed arthritis
and arthritis-attributable activity limitation --- United States, 2007-2009. MMWR. Morb.
Mortal. Wkly. Rep. 59, 1261–5 (2010).

16.

McDonough, C. M. & Jette, A. M. The Contribution of Osteoarthritis to Functional
Limitations and Disability. Clin. Geriatr. Med. 26, 387–399 (2010).

17.

McCurry, S. M. et al. Frequency of comorbid insomnia, pain, and depression in older adults
with osteoarthritis: Predictors of enrollment in a randomized treatment trial. J. Psychosom.
Res. 71, 296–299 (2011).

18.

Gs, M. & Mologhianu G. Osteoarthritis pathogenesis-a complex process that involves the
entire joint. J. Med. Life 7,

19.

Loeser, R. F., Goldring, S. R., Scanzello, C. R. & Goldring, M. B. Osteoarthritis: A disease
of the joint as an organ. Arthritis Rheum. 64, 1697–1707 (2012).

20.

Blagojevic, M., Jinks, C., Jeffery, A. & Jordan, K. P. Risk factors for onset of osteoarthritis
of the knee in older adults: a systematic review and meta-analysis. Osteoarthr. Cartil. 18,
24–33 (2010).

21.

Vaishya, R., Pariyo, G. B., Agarwal, A. K. & Vijay, V. Non-operative management of
osteoarthritis of the knee joint. J. Clin. Orthop. trauma 7, 170–6 (2016).

22.

Rönn, K., Reischl, N., Gautier, E. & Jacobi, M. Current surgical treatment of knee
osteoarthritis. Arthritis 2011, 454873 (2011).

23.

Glasson, S. S., Blanchet, T. J. & Morris, E. A. The surgical destabilization of the medial
meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthr. Cartil. 15,
1061–1069 (2007).

24.

Kim, T. H. et al. Mig-6 suppresses endometrial cancer associated with pten deficiency and
ERK activation. Cancer Res. 74, 7371–7382 (2014).

25.

Welch, I. D., Cowan, M. F., Beier, F. & Underhill, T. M. The retinoic acid binding protein
CRABP2 is increased in murine models of degenerative joint disease. Arthritis Res. Ther.
11, R14 (2009).

26.

Glasson, S. S., Chambers, M. G., Van Den Berg, W. B. & Little, C. B. The OARSI
histopathology initiative – recommendations for histological assessments of osteoarthritis
in the mouse. Osteoarthr. Cartil. 18, S17–S23 (2010).

27.

Driban, J. B., Sitler, M. R., Barbe, M. F. & Balasubramanian, E. Is osteoarthritis a
heterogeneous disease that can be stratified into subsets? doi:10.1007/s10067-009-1301-1

28.

Dell’Isola, A., Allan, R., Smith, S. L., Marreiros, S. S. P. & Steultjens, M. Identification of

188
clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC
Musculoskelet. Disord. 17, 425 (2016).
29.

Chen, D. et al. Osteoarthritis: toward a comprehensive understanding of pathological
mechanism. Nat. Publ. Gr. 5, (2016).

30.

Guilak, F. Biomechanical factors in osteoarthritis. Best Pract. Res. Clin. Rheumatol. 25,
815–23 (2011).

31.

Feng, X. Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and
Disease. Curr. Chem. Biol. 3, 189–196 (2009).

32.

Bader, D. L., Salter, D. M. & Chowdhury, T. T. Biomechanical influence of cartilage
homeostasis in health and disease. Arthritis 2011, 979032 (2011).

33.

Miller, R. E. et al. CCR2 chemokine receptor signaling mediates pain in experimental
osteoarthritis. Proc. Natl. Acad. Sci. U. S. A. 109, 20602–20607 (2012).

34.

Jia, H. et al. EGFR signaling is critical for maintaining the superficial layer of articular
cartilage and preventing osteoarthritis initiation. Proc. Natl. Acad. Sci. U. S. A. 201608938
(2016). doi:10.1073/pnas.1608938113

35.

Jia, H. et al. Subchondral bone plate sclerosis during late osteoarthritis is causedby loadinginduced reduction in Sclerostin. Arthritis Rheumatol. (Hoboken, N.J.) 70, 230 (2018).

36.

Zhang, X. et al. Reduced EGFR signaling enhances cartilage destruction in a mouse
osteoarthritis model. Bone Res. 2, 14015 (2014).

37.

Usmani, S. E. et al. Context-specific protection of TGFα null mice from osteoarthritis. Sci.
Rep. 6, 30434 (2016).

38.

Appleton, C. T. G. et al. Reduction in Disease Progression by Inhibition of Transforming
Growth Factor α-CCL2 Signaling in Experimental Posttraumatic Osteoarthritis. Arthritis
Rheumatol. 67, 2691–2701 (2015).

39.

Qin, L. & Beier, F. EGFR Signaling: Friend or Foe for Cartilage? JBMR Plus 3, e10177
(2019).

189

Chapter 5
Discussion
5.1

Overview

The overall objective of my thesis was to examine the role of mitogen inducible gene 6 (Mig-6)
in cartilage biology and osteoarthritis (OA). Initially, our laboratory identified transforming
growth factor alpha (TGFα), which is a ligand for epidermal growth factor receptor (EGFR), in
microarray studies from cartilage isolated from a surgical rat model of OA (1,2). Our studies
have shown that TGFα mRNA levels were almost 4-fold enhanced in the OA animals (2).
Additional studies demonstrated that TGFα was amongst the genetic loci most strongly linked to
hip OA and cartilage thickness in two genome-wide association studies (GWAS) (3,4). Based on
these findings, our laboratory decided to investigate the role of EGFR signaling in cartilage
development, homeostasis, and disease in detail (5–7). The next logical step was to investigate
a negative regulator of EGFR signaling named Mig-6 (encoded by the gene Errfi1) (8,9).
Our and other previous data supports the hypothesis that Mig-6 plays a key role in cartilage
homeostasis. Global Mig-6 mouse knockout (KO) lines had demonstrated progressive cartilage
degeneration similar to that seen in OA (10,11). Furthermore, cartilage-specific deletion of Mig6 resulted in anabolic and catabolic phenotypes similar to previous studies using whole body
Mig-6 KO models, such as increased articular cartilage thickness and formation of osteochondral
nodules in their knee joints and spine (12). Mig-6 KO mice demonstrated activation of EGFR
and increased expression of SOX9 and PCNA, both in nodule cells and in articular cartilage.
Previous research demonstrates that Mig-6 overexpression acts as a negative feedback regulator
of EGFR/ERK signaling (13), but these studies did not yet analyze joint tissues.
The first study in my thesis, I generated mice with cartilage-specific Mig-6 overexpression (14).
Mice with conditional (‘over’) Mig-6 alleles (Mig-6over/over) were bred to mice expressing Cre
recombinase under the control of the Collagen 2 promoter and overexpressing mice were
obtained at the expected Mendelian ratios. I began by examining Mig-6 over/over mice during early
postnatal development and comparing them to control mice. I examined skeletal development
and cartilage development at post-natal day 0 (P0), 6 weeks-old, 11 weeks-old, 12 and 18 months
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of age and I observed no obvious gross malformations or growth plate alterations in Mig-6over/over
mice at developmental stages. However, long bones of Mig-6over/over mice were significantly
shorter than those of control mice at the ages of 6 and 11 weeks as well as at 12 and 18 months.
Furthermore, articular cartilage from 6 and 11 weeks-old male and female mice appeared healthy
during skeletal maturity. However, examination of the knee joints of Mig-6over/over did show
increased cartilage loss relative to controls at the ages of 12 and 18 months.
Therefore, overexpression of Mig-6 resulted in early OA-like pathology, in particular in male
mice. Interestingly, immunostaining for SOX9, phosphoEGFR and lubricin (PRG4) was
decreased in articular cartilage of Mig-6over/over mice whereas MMP13 staining was increased in
areas of cartilage degeneration. Importantly, reduced SOX9 staining preceded histological
cartilage degeneration, suggesting a potential mechanism for OA progression in our mutant mice.
Taken together, this led me to conclude that Mig-6 plays an important role for initiating the OAphenotype onset, likely through the activation of the EGFR pathway.
Second, we utilized Prx-1 Cre to drive the overexpression of Mig-6 in the entire limb
mesenchyme with the same Mig-6over/over line (14) used in my previous study. My rationale was
that overexpression in multiple joint tissues might have additional effects, in comparison to
overexpression in cartilage only. Mig-6over/over mice displayed minor differences in body weight
in comparison to controls. Surprisingly, these mice showed similar bone length at 12 and 36
weeks-old, despite earlier and more widespread Cre activity compared to the Col2 Cre driver.
However, the thickness of the calcified articular cartilage in the medial femoral condyle (MFC)
and medial tibial plateau (MTP) of male Mig-6 over/over mice was statistically significantly lower
than in controls. I evaluated the knee joints of 36 weeks-old Mig-6

over/over

male mice that

displayed increased articular cartilage damage in comparison to the control group. Again, male
mice showed a stronger and more consistent phenotype than the female group. Interestingly, use
of the Prx-1 Cre resulted in more damage on the lateral side of the knee joint compared to Col2Cre, possibly due to overexpression of Mig-6 in additional joint structures. Measurement of the
subchondral bone area in male Mig-6 over/over and control mice showed no differences. However,
examination of picrosirius red staining under polarized light showed that the structure of the
articular cartilage ECM in Mig-6

over/over

was altered compared to that of control mice. The

articular cartilage of control animals showed greenish/yellow birefringence, while that from Mig-
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6 over/over animals showed fewer green collagen fibers, indicating a loss of normal collagen fiber
organization. The resulting collagen network alterations may have an influence on the structural
integrity of the cartilage and lead to degenerative pathologies (15). Immunohistochemistry for
SOX9 and PRG4 showed decreased staining in Mig-6over/over mice relative to controls, providing
potential molecular mechanisms for the observed effects. Moreover, MMP13 immunostaining
appeared increased in Mig-6over/over mice in the areas of damage on the medial side.
Lastly, we surgically induced OA in cartilage-specific Mig-6 overexpressing male mice at 16
weeks of age through destabilization of medial meniscus surgery (DMM). This surgery is the
most accepted and a widely surgical OA model in mice in order to induce secondary OA that
develops gradually in the medial compartment (16). Our results showed that cartilage
degeneration is more severe in Mig-6 overexpressing mice than in control littermates 8 weeks
post surgery). Interestingly, while both surgery and Mig-6 overexpression did not affect most
parameters assessed in Open Field testing, Mig-6 overexpression did reduce vertical activity
(rearing) both after SHAM and DMM surgery.

5.2

Contribution to the Field of Osteoarthritis

Through this thesis, I characterise for the first time the role of Mig-6 overexpression on joint
health. In Chapter 2 and 3, I present work where I discovered that Mig-6over/over mice did not have
major effects on cartilage development and bone growth. However, Mig-6over/over disrupts normal
cartilage maintenance and homeostasis. For both of these chapters, I employed an aging model
of OA by analyzing spontaneous joint disease.
In chapter 2, I used chondrocyte-specific overexpression of Mig-6. Prior to our investigation,
systemic deletion of Mig-6 had been implicated in progressive joint disease with chondroosseous growths in the ankle, temporomandibular joint (TMJ) and knee (11,17). Moreover,
studies utilizing Col2a1-Cre to drive deletion of Mig-6 in chondrocytes have shown increased
articular cartilage thickness and invasive chondro-osseous nodules with overactive EGFR
signaling and induction of SOX9 immunostaining (12,18). Additionally, in chapter 3, I
investigate the role of Mig-6 overexpression utilizing Prx1-Cre to drive overexpression of Mig6 in the entire limb mesenchyme. Furthermore, SOX9 and PRG4 immunostaining seems to be
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decreased in articular cartilage of 12-week-old mice and even more in 36-week-old mice when
cartilage shows signs of degeneration. Chapter 4 provides the first report on the effect of
chondrocyte-specific overexpression of Mig-6 on post-traumatic OA. Our data demonstrated that
Mig-6 overexpression worsened cartilage degeneration after DMM surgery.
Collectively, my data provide strong evidence that Mig-6 overexpression accelerates OA both
during aging (primary OA) and after injury (secondary/post-traumatic OA). These effects are
most likely due to decreased activation of EGFR signaling, as they resemble effects seen upon
genetic inactivation of EGFR (19,20). Lastly, my findings from this thesis further emphasize that
the Mig-6/EGFR network is a major regulator of cartilage homeostasis and OA, but many aspects
of its action in cartilage are still not well understood (see next section).

5.3
5.3.1

Limitations of Research
Limitations of in-vivo models

The use of small animal model such as rodent models gives us the opportunity to study the role of
a protein/gene using transgenic and knockout strains in a disease model. While we can control
many variables in these studies, some are outside our control such as litter size and certain aspects
of behavior. I tried to minimize the effects of these variations and to keep transgenic mice and
controls under identical conditions. For example, I co-housed the control animals with their
respective Mig-6 overexpressing littermates wherever possible. These models have allowed us to
evaluate the function of Mig-6 in cartilage and the whole joint. In chapters 2 and 4, I used the
collagen II promoter to drive Cr expression and activation of Mig-6 overexpression. This Cre line
is not fully cartilage specific since recombination can occur in other joint cells as well as
osteoblasts and osteocytes that develop from trans-differentiation of chondrocytes (21,22). In
addition, this Cre driver becomes activated during development (before birth); thus, it can be
difficult to distinguish developmental defects from OA-specific effects in adult articular cartilage.
One way to overcome this in the future is the use of an inducible Cre-driver, such as the Aggrecan
CreER and postnatal tamoxifen injection (23). Similar concerns and solutions apply to the Prx1
Cre driver used in chapter 3.
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Currently, studies in chapters 2 and 3 use partially different time points/ages for analyses. For
example, the eldest animals analyzed in chapter 2 were 18 months, while maximum age was 9
months in chapter 3. This limitation was due to different breeding schedules between the two
lines, but future studies should aim to align time courses for both to allow direct comparison of the
effects of the two different Cre drivers. Ideally, validation of results in a different genetic
background would strengthen the conclusions. For feasibility, PTOA studies in chapter 4 were
only done in male mice; ideally these should be done in female mice. Additional time points (4,12,
and 16 weeks after surgery) should also be included into this study, as well as analyses of additional
tissues (subchondral bone, synovium etc.).

5.3.2

Limitations of outcome measures

One major limitation of our analyses is the absence of a reliable Mig-6 antibody that would allow
us to 1) quantify the level of Mig-6 protein overexpression; and 2) to localize where in the joint
Mig-6 protein is expressed. However, none of the antibodies we tested were specific enough (e.g.
they all gave strong signals from confirmed Mig-6 KO tissues). Other molecular techniques
including qPCR, Western Blotting, etc. also could be used in the future. to provide more insights
into the molecular mechanisms mediating Mig-6 effects in cartilage and other joint tissues.
Imaging modalities such as high resolution microCT could be included to allow more quantitative,
three-dimensional analyses of bony changes in our animals. Mechanical testing, for example by
atomic force microscopy, could provide another readout of high physiological relevance. Our
Open Field studies demonstrated minimal changes between groups in chapter 4, and none that
could be attributed to DMM surgery. Additional measures that more directly examine pain (such
as von Frey filaments or hot/cold plate assays) could be considered in the future to establish a more
direct link between structural damage and pain.

5.4

Future Directions

My results implicate the need for several follow-up studies. In addition to those already
mentioned in the last section (such as more time points and inclusion of female mice in DMM
studies, additional molecular analyses and pain assays etc.), several larger questions should be
tackled. My studies demonstrated that overexpression of Mig-6 accelerates both primary and
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secondary OA and implicated reduced EGFR signaling and downregulation of SOX9 expression
as potential mechanisms. However, detailed mechanistic studies are required to characterise the
molecular pathways involved. We have proposed that the phenotypes seen in our Mig-6
overexpressing mice are due to reduced EGFR signaling. Downstream pathways mediating these
activities, such as ERK1/2 or PI3K, should be investigated in detail using biochemical and cell
biological assays. However, since Mig-6 interacts with a number of other potential candidates,
e.g. the other EGFR family receptors (ErbB1-4), cMET, c-Abl and Cdc42 (24,25), we should
also investigate whether any of these pathways are deregulated and contribute to the observed
phenotypes. This might include the generation of double mutant mice to determine whether
manipulation of these factors can rescue the phenotypes of the Mig-6 overexpressing mice (or
the Mig-6 KO mice).
Aging-associated OA and post-traumatic OA are only two of several osteoarthritis subtypes. Both
Mig-6 KO and overexpressing mice should also be tested in models of metabolic OA (e.g. on a
high fat or western diet), and overuse-induced OA (e.g. treadmill running), both of which are
established in our laboratory. Moreover, Mig-6 function should be examined in human samples,
through knockdown and/or overexpression studies in isolated joint cells. While there are currently
no drugs that directly affect Mig-6 activity, genetic strategies to inhibit its expression (shRNA or
CRISPR/Cas9) could be attempted in the future. Any such attempts would have to be very tightly
controlled both spatially and temporarily, because of the dual catabolic and anabolic role of EGFR
signaling in the joint (5). This dual role, where EGFR has been shown to both protect from and
promote OA dependent on the context, remains poorly understood. My studies clearly suggest a
protective role of the pathway – if we inhibit EGFR signaling by overexpressing Mig-6, we see an
acceleration in OA progression. However, strong evidence for a catabolic role of the same
pathways has been provided by our lab and others (6,19,26–28). Understanding the basis of this
dual role will likely require detailed mechanistic studies at the biochemical level, as well as more
in vivo studies using crosses of multiple mouse lines, along with the use of tamoxifen-inducible
Cre drivers that allow for precise activation or inactivation of genes.
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